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Epstein-Barr virus (EBV) is highly ubiquitous in human population and establishes a
lifelong asymptomatic infection within the infected host unless the immune system
is compromised. Following initial infection in the oropharyngeal epithelial cells, EBV
primarily infects naive B-lymphocytes and develops a number of B-cell lymphomas
particularly in immune-deficient individuals. In vitro, EBV can also infect and subsequently
transform quiescent B-lymphocytes into continuously proliferating lymphoblastoid cell
lines (LCLs) resembling EBV-induced lymphoproliferative disorders in which a subset of
latent transcripts are detected. Genetic studies revealed that EBNA-3 family comprising
of three adjacent genes in the viral genome—EBNA-3A and -3C, but not -3B, are critical
for B-cell transformation. Nevertheless, all three proteins appear to significantly contribute
to maintain the overall proliferation and viability of transformed cells, suggesting a critical
role in lymphoma development. Apart from functioning as important viral transcriptional
regulators, EBNA-3 proteins associate with many cellular proteins in different signaling
networks, providing a suitable platform for lifelong survival of the virus and concurrent
lymphoma development in the infected host. The chapter describes the function of each
these EBV nuclear antigen 3 proteins employed by the virus as a means to understand
viral pathogenesis of several EBV-associated B-cell malignancies.
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INTRODUCTION
Epstein-Barr virus (EBV) nuclear antigen, EBNA-3, comprising of three closely related proteins
namely EBNA-3A, -3B, and -3C, was suggested to be generated by a series of gene duplication
events during gammaherpesvirus evolution as they share limited but significant amino acid (aa)
sequence homology (Saha and Robertson, 2013). Interestingly, unlike of the other viral genes there
are no known viral homologs in other closely related primate lymphocryptoviruses. They share a
similar gene structure with a shorter 5′- and a longer 3′-exons arranged in a tandem array in the
EBV episome. All EBNA-3 transcripts are alternatively spliced from very long mRNAs initiated
at the latency C-promoter (Cp), which is active in EBV transformed lymphoblastoid cell lines
(LCLs) but blocked in several EBV-associated cancers through hypermethylation [reviewed in
(Robertson et al., 1995; Saha and Robertson, 2013; Allday et al., 2015)]. Although, EBNA-3 proteins
demonstrated extensive redundant biological functions, genetic studies using recombinant viruses
revealed that only EBNA-3A and -3C but not -3B are essential for B-cell transformation in vitro
(Maruo et al., 2005, 2006, 2011; Saha and Robertson, 2013).
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Initial Detection of EBNA-3 Proteins in EBV
Infected B-Cells
The EBNA-3 proteins or rather EBNA-3 was initially identified
as an extra 142-kDa band along with other previously identified
latent proteins—EBNA-1, EBNA-2 and LMP-1, in latently
infected B-cell cultures using EBV positive patient’s sera
(Hennessy et al., 1985). Initial experiments demonstrated that
EBNA-3 was generated from the BamHI digested fragment
(named as ‘E’) Rightward open reading Frame 1 (BERF1) of
EBV episome (reviewed in Hennessy et al., 1986; Saha and
Robertson, 2013). Interestingly, a number of human sera were
tested demonstrated slightly higher molecular weights than
EBNA-3 that was previously detected, signifying that EBNA-
3 might be composed of several related proteins within same
family in EBV transformed B-lymphocytes. Following studies
demonstrated that indeed EBNA-3 was composed of three
proteins—in addition to the initially identified BERF1 fragment
encoding EBNA-3A, BamHI BERF2b fragment expressed a
165 kDa protein named EBNA-3B (or EBNA-4) and the most
rightward short and long BamHI E fragments (BERF3 and
BERF4) expressed a 155 kDa protein named EBNA-3C (or
EBNA-6) (Petti and Kieff, 1988; Petti et al., 1988; Saha and
Robertson, 2013). Interestingly, EBNA-3C was detected nearly in
all EBV positive B-cells except Raji as it was found later that there
was a deletion of the BERF4 segment of the EBV episome in this
cell line (reviewed in Saha and Robertson, 2013).
EBNA-3 Proteins Are Restricted to Nucleus
Sub-cellular localization of all EBNA-3 proteins was found to be
restricted to the nucleus using affinity chromatography purified
human anti-sera. Subsequent studies in order to delineate
the functional domains of EBNA-3A demonstrated that the
aa residues 147-157 contain a nuclear localization sequence
(NLS). Computational prediction analyses in combination with
molecular cell biology experiments using GFP-tagged constructs
and site directed mutagenesis further confirmed that EBNA-
3A contains 5, EBNA-3B contains 2 and EBNA-3C contains 3
functional NLSs (Krauer K. et al., 2004; Buck et al., 2006; Burgess
et al., 2006).
EBNA-3 Expression Is Restricted to
Latency III Program
The characterized expression pattern of latent genes in EBV-
transformed LCLs is known as “latency-III program.” This
pattern is also observed in most of the post-transplant
and immune-compromized patients’ associated EBV positive
lymphomas. In this program, all the latent genes are expressed—
a subset of 12 transcripts, which include six nuclear proteins
EBNA-1, EBNA-2, EBNA-3A, EBNA-3B, EBNA-3C, and EBNA-
LP, three membrane proteins LMP-1, LMP-2A, and LMP-
2B along with three non-coding unpolyadenylated transcripts
EBER-1 and EBER-2, and BARTs (Saha et al., 2010; Saha and
Robertson, 2011a). Although infected cells contain only a few
copies of EBNA-3 transcripts, the EBNA-3 protein products are
relatively stable in vivo. It has been demonstrated that the latency-
III program can be simultaneously developed in conjunction
with acute EBV infection in nascent B-cells prior to the proper
establishment of latently infected memory B-cells, which serves
as a latent reservoir of virus particles and subject to temporal
activation of different latency programs (Young and Rickinson,
2004).
EBNA-3A and -3C, But Not -3B, Are
Essential for In vitro B-Cell Transformation
A series of experiments using genetically engineered viruses
confirmed that only EBNA-3B of EBNA-3 proteins can be
expendable for EBV-mediated B-cell growth transformation
in vitro (Chen et al., 2005; Maruo et al., 2006, 2011).
Initial molecular biology experiments with recombinant EBV
containing stop codons inserted into the ORFs of other
family members established that both EBNA-3A and -3C
are indispensable for B-cell growth transformation in vitro
(Tomkinson et al., 1993). Whilst recombinant virus encoding
an EBNA-3A protein with a stop codon inserted after aa 302
lost its ability to transform naive B-cell, a parallel expression
of wild-type EBNA-3A was typically shown to restore the
transforming ability of the mutant virus. In corroboration to
this, kempkes et al. also demonstrated the importance of EBNA-
3A in maintaining EBV transformed B-cell outgrowth using a
71 kbp of EBV episome termed as mini-EBV with a single C
residue deleted at EBNA-3A ORF (Kempkes et al., 1995). Similar
studies using recombinant virus containing a stop codon at aa
365 in EBNA-3C ORF demonstrated its essentiality in B-cell
transformation, whereas recombinant virus encoding an EBNA-
3B protein with a stop codon inserted after aa 109 was unable to
show any difference in B-cell transformation when compared to
wild-type virus (Tomkinson and Kieff, 1992; Tomkinson et al.,
1993). In addition, recently EBNA-3B was rather described as a
tumor suppressor protein in comparison to an intense oncogenic
activities exerted by the other two family members EBNA-3A
and -3C (reviewed in Allday et al., 2015).
Although, EBNA-3B was shown to dispensable for EBV-
induced B-cell growth transformation, fascinatingly all
the EBNA-3 proteins were recognized as major antigenic
targets for cytotoxic T-cell (CTL) responses against EBV-
transformed B-lymphocytes (Murray et al., 1992), signifying the
importance of each of the EBNA-3 members in primary EBV-
infection and subsequent B-cell lymphoma development.
Herein we aim to summarize the work of more than
two decades focussing on EBNA-3 proteins in terms of
their molecular interactions with multiple host cellular
networks.
TRANSCRIPTIONAL REGULATION
EBNA-3 Proteins Are Non-DNA Binding
Potent Transcriptional Regulators
Regardless of their minimal structural resemblance, all EBNA-3
proteins function as transcriptional regulatory proteins through
interacting with numerous cellular DNA binding proteins and
other accessory transcription factors, instead of directly bind to
the DNA (Table 1).
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TABLE 1 | EBNA-3 interacting cellular partners.
Interacting proteins Deregulated function References
EBNA-3A
RBP-Jk Recruits RBP-Jκ activity to regulate both viral and cellular
gene transcription
Robertson et al., 1996; Maruo et al., 2005; Calderwood
et al., 2011
CtBP Recruits CtBP to regulate gene transcription, for example
p16INK4A
Hickabottom et al., 2002; Skalska et al., 2010
Chk2 Releases G2/M cell-cycle block Krauer K. G. et al., 2004b
WDR48, WDR20, and USP46/UP12 Forms a deubquitylation complex consisting of WDR48,
WDR20, and USP46/USP12), possibly required to maintain
LCL outgrowth
Ohashi et al., 2015
MIZ-1 Blocks the interaction between MIZ-1 and nucleophosmin
and overall inhibits p15INK4B expression
Bazot et al., 2014
20S proteasome Not yet described Touitou et al., 2005
Chaperones Induces all of the factors necessary for an active Hsp70
chaperone complex including Hsp70, Hsp70B/B′, Bag3,
and DNAJA1/Hsp40
Young et al., 2008
XAP-2 Increased nuclear localization; however, precise function
has not yet been described
Kashuba et al., 2000
TCP-1 Not yet described Kashuba et al., 1999
AhR Enhances ligand dependent transactivation Kashuba et al., 2006
UK/UPRT Increased nuclear localization; however, precise function
has not yet been described
Kashuba et al., 2002
EBNA-3B
RBP-Jκ Recruits RBP-Jκ activity to regulate both viral and cellular
gene transcription
Robertson et al., 1996
Cyclin A Not yet described Knight and Robertson, 2004
WDR48, WDR20, and USP46/UP12 Forms a deubquitylation complex consisting of WDR48,
WDR20, and USP46/USP12)
Ohashi et al., 2015
20S proteasome Not yet described Touitou et al., 2005
EBNA-3C
RBP-Jκ Recruits RBP-Jκ activity to regulate both viral and cellular
gene transcription
Robertson et al., 1996; Lee et al., 2009; Calderwood et al.,
2011; Kalchschmidt et al., 2016
CtBP Recruits CtBP to regulate gene transcription, for example
p16INK4A
Touitou et al., 2001; Lee et al., 2009
Prothymosin-α Recruits prothymosin-α along with p300 to regulate gene
transcription
Cotter and Robertson, 2000
p300 Recruits p300 activity to regulate cellular gene transcription Subramanian et al., 2002a
Gemin3/DDX20 Stabilizes and promotes a complex formation with p53 and
thereby negatively affecting p53 transcriptional activity
Cai et al., 2011
HDAC1 and HDAC2 Recruits HDAC1/2 activity to regulate cellular gene
transcription
Radkov et al., 1999; Knight et al., 2003
mSin3A and NCoR Functions in a complex with mSin3A and NCoR and
represses transcription, for example p16INK4A
Knight et al., 2003; Jiang et al., 2014
Spi1/PU1 Recruits to regulate both viral and cellular gene transcription Zhao and Sample, 2000
Nm23-H1 Modulates intrinsic transcriptional and anti-metastatic
activities
Subramanian et al., 2001
20S proteasome Not yet described Touitou et al., 2005
Cyclin A Enhances Cyclin A/CDK2 kiase activity Knight and Robertson, 2004; Knight et al., 2004
Cyclin E Not yet described Knight et al., 2004
Cyclin D1 Enhances the kinase activity of Cyclin D1/CDK6 which
enables subsequent ubiquitination and degradation of pRb
Knight et al., 2004; Saha et al., 2011b
GSK3β Increases Cyclin D1 nuclear localization by blocking GSK3β
activity
Saha et al., 2011b
p53 Blocks p53 mediated transcriptional and apoptotic activities Saha et al., 2009, 2011a; Yi et al., 2009
Mdm2 Enhances the intrinsic ubiquitin ligase activity of Mdm2
toward p53
Saha et al., 2009
ING4 and ING5 Suppresses both ING4 and ING5 assisted p53
transcriptional activity
Saha et al., 2011a
(Continued)
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TABLE 1 | Continued
Interacting proteins Deregulated function References
E2F1 Represses E2F1 transcriptional activity in response to DNA
damage signals
Saha et al., 2012
pRb Facilitates pRb degradation in an ubiquitin-proteasome
manner
Knight et al., 2005a
Chk2 Releases the G2/M checkpoint block of cell-cycle Choudhuri et al., 2007; Nikitin et al., 2010
Gadd34 Activates the upstream component of the UPR
(eIF2α-phosphorylation) and blocks downstream UPR
events (XBP1 activation and ATF6 cleavage)
Garrido et al., 2009
SCFSkp2 Recruits of SCFSkp2 E3 ligase activity to facilitate
degradation of p27KIP1 and pRb
Knight et al., 2005a,b
c-Myc Stabilizes and enhances transcription Bajaj et al., 2008
Sumo1/3 Recruits SUMO-1/3 for EBNA-2 mediated transctivation Rosendorff et al., 2004
MRPS18-2 Releases E2F1 and thereby facilitates G1-S transition of the
cell-cycle
Kashuba et al., 2008
Aurora kinase B Negatively regulates p53 and pRb activities through
stabilizing Aurora kinase B activity
Jha et al., 2013, 2015
IRF4/8 Stabilizes IRF4 and dowregulates IRF8; Recruits for
modulating cellular gene transcription
Banerjee et al., 2013; Jiang et al., 2014
H2AX Destabilizes H2AX and restricts H2AX expression into
nucleus
Nikitin et al., 2010; Jha et al., 2014
USP46/USP12 Recruits USP46/USP12 dubiquitination activity to regulate
p14ARF transcription
Ohashi et al., 2015
p73 Blocks p73 mediated apoptosis Sahu et al., 2014
RBP-JK—A Common Mediator of EBNA-3
Mediated Transcriptional Repression
A large number of interacting proteins for EBNA-3 have been
identified and subsequently suggested to be crucial for EBV
induced B-cell transformation. Of these, RBP-JK (or CBF1), a
downstream regulator of Notch signaling pathway, was the first
established transcription factor required for LCL growth (Lee
et al., 2009; Maruo et al., 2009). The initial clue that EBNA-3
proteins can function as transcriptional regulators was derived
from the seminal observation that all EBNA-3 proteins share
a common binding site of RBP-JK (Waltzer et al., 1996; Saha
and Robertson, 2013). EBNA-2, another essential latent antigen
for in vitro B-cell transformation, was also found to act as a
non-DNA binding transcriptional activator for both viral (LMP-
1 and LMP-2) and cellular genes (CD23) through recruiting
RBP-JK activity (Wang et al., 1991; Waltzer et al., 1996).
Interestingly, all three EBNA-3 proteins can antagonize EBNA-2
induced transcriptional activation through competing with RBP-
JK binding (Waltzer et al., 1996). Using simple reporter assays
it has later been revealed that all EBNA-3 proteins are strong
transcriptional repressors. Most of the earlier work on EBNA-3
mediated transcriptional repression was particularly focussed on
EBNA-3C protein. Two putative repressive domains for EBNA-
3C have been identified—one lies at aa 280-525 represents
as strong repressor domain and another lies at aa 580-992
represents as relatively weaker repressive domain (Subramanian
et al., 2002b; West, 2006; Saha and Robertson, 2013). As similar
to EBNA-3C, an inherent transcriptional repression domain
of EBNA-3A was mapped within aa 100-364. Additionally,
a RBP-JK-independent repression domain of EBNA-3A was
also mapped to aa 524-666. For example, EBNA-3A can
efficiently suppress EBNA-2 mediated activation from the EBV
Cp promoter, while the repressive effect was not observed once
the RBP-JK binding site in the promoter region was absent
(Cludts and Farrell, 1998). Given the viral Cp promoter regulates
the transcription of all EBNA genes, it can be easily speculated
that the EBNA-3 proteins might have an auto-regulatory function
in order to control their own expression in latently infected
B-lymphocytes.
All the three EBNA-3 proteins were shown to interact with
RBP-JK through their homology sequences located at the N-
terminal region (Robertson et al., 1996; Waltzer et al., 1996). In
case of EBNA-3A, the binding domain was mapped at aa 1-138,
in which aa 125-138 were found to be important (Bourillot et al.,
1998). Interestingly, several other groups subsequently mapped
the RBP-JK binding domain spanning different aa residues
located either at 173-223 or 224-566 of EBNA-3A (Zhao et al.,
1996). The RBP-JK binding domain of EBNA-3B was mapped at
the conserved N-terminus region spanning aa 1-311 (Robertson
et al., 1996). Likewise EBNA-3C binding domain to RBP-JK has
also been mapped at the N-terminal region spanning amino
acid residues 1-183 (Robertson et al., 1996). Interestingly, all
the EBNA-3 proteins were shown to interact with a RBP-JK
homolog, RBP-2N (Krauer et al., 1996). However, the functional
significance of these interactions is not yet explored.
More recently, it has been clearly demonstrated the interaction
between EBNA-3 proteins with RBP-JK is vital for maintaining
LCL growth, where EBNA-3 mediated suppression of EBNA-2
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induced Cp promoter might play an important role (Maruo
et al., 2005, 2009). LCLs established with recombinant viruses
that have deleted portions of both EBNA-3A and -3C binding
sites for RBP-JK were unable to grow, whereas ectopic expression
of individual wild-type cDNAs maintained the proliferation
(Maruo et al., 2005, 2009). However, whether two seemingly
different functions - EBNA-3 mediated suppression of EBNA-2
transactivation and LCL growth maintenance are directly linked
to each other remain an open question. This is only can be
answered when the complete molecular profile of these protein
complexes would be identified in near future.
Transcriptional Activation—Intrinsic
Activity and Structural Resemblance with
bZIP Domain
In addition to transcriptional repression, EBNA-3C can also
function as a transcriptional activator. For example, EBNA-
3C mediated transactivation of LMP-1 promoter, although this
activity was seemed to be independent of RBP-JK interaction.
Initial experiments using EBNA-3 proteins in order to unravel
its effect on phenotypic changes in B-cell surface markers
led to the discovery of EBNA-3C induced CD21 expression
(Allday et al., 1993). The activation domain of EBNA-3C was
mapped within the C-terminal aa 724-826, which shares a
sequence homology with the transactivation domain of cellular
transcription factor Sp1 (Marshall and Sample, 1995). However,
the transactivation ability was not as strong as its repression.
EBNA-3C was further recognized as a strong transcriptional
regulator by showing interaction with a TATA-box binding
protein, or containing a basic leucine zipper (bZIP) sequence
located within the N-terminal residues 244-291 (West, 2006).
However, the EBNA-3C bZIP domain portrays a non-canonical
bZIP sequence without any appropriate sequence homology or
structural resemblance with any known cellular bZIP domains,
apart from a tandem repeats of four leucine residues (Amoutzias
et al., 2007). Perhaps the lack of DNA binding ability of
EBNA-3C corroborates the lack of proper bZIP sequence
homology. Further in depth analyses of this bZIP domain
through typical biochemical methods such as circular dichroism
(CD) spectroscopy and analytical ultracentrifugation imply that
this domain does not form stable coiled-coil structures or
promote dimerization, which are the common characteristics
among well-known leucine zipper domains of DNA binding
transcription factors (West, 2006; Amoutzias et al., 2007). On
the other hand, substitution of the repeated four leucine residues
with prolines resulted in dramatic reduction of RBP-JK binding
and also resulted in a change in the length of the predicted
helical structure of the zipper. Likewise, modifications in the
charged residues of the basic portion of the EBNA-3C bZIP
domain inhibited the RBP-JK interaction and so as EBNA-
3C mediated transcriptional repression (West, 2006; Saha and
Robertson, 2013). These results suggests that though EBNA-
3C contains a non-canonical bZIP sequence which affect the
DNA-binding ability, maintaining proper secondary and tertiary
structure within this sequence is essential for downstream
activity.
Carboxy-terminal Binding Protein (CtBP)
CtBP, initially identified as adenovirus E1A Carboxy-terminal
Binding Protein, is a transcriptional co-repressor that can adapt
a transcriptionally active chromatin into a transcriptionally
silent state (Chinnadurai, 2002, 2009). CtBP is now referred
as two closely related transcription factors - CtBP1 and CtBP2
(Chinnadurai, 2002, 2009). Although these two proteins share a
substantial aa sequence homology, it is yet to be known that at
what extent these proteins are functionally redundant. However,
unquestionably both proteins largely function as transcriptional
co-repressors and being recruited by factors that have the
conserved CtBP-binding ProLeu-Asp-Leu-Ser “PLDLS” motif
(Chinnadurai, 2002, 2009). Both EBNA-3A and -3C were shown
to strongly interact with CtBP1 via the CtBP binding motifs.
As both EBNA-3C and EBNA-3A interact with CtBP1 via the
typical CtBP binding motif (Touitou et al., 2001; Hickabottom
et al., 2002), it is conceivable that they also can form complex
with CtBP2. However, to the best of our knowledge this has
not yet been verified. The initial functional relevance of this
conserved motif was determined using simple reporter assays.
In contrast to the wild-type EBNA-3C, deletion mutant amino
acid residues 728-732 “PLDLS” fused with Gal4 DNA binding
domains resulted in activation of a CAT reporter, suggesting
that CtBP1 might play a critical role in attenuating the EBNA-
3C transactivation domain at the C-terminal region (Touitou
et al., 2001). Moreover, alteration of this conserved region also
impaired the transforming ability of EBNA-3C in cooperation
with oncogenic Ha-ras (Saha and Robertson, 2013). In contrast
to EBNA-3C, EBNA-3A contains two non-consensus bipartite
CtBP binding motifs located at the C-terminal region spanning
aa 857-861 “ALDLS” and 886-890 “VLDLS” (Hickabottom et al.,
2002). As similar to EBNA-3C, these binding residues of EBNA-
3A were found to be critical for both transcriptional repression
as well as transforming ability (Hickabottom et al., 2002).
Nevertheless, the precise role of CtBP1 in EBNA-3 regulated B-
cell transformation process became more evident when analysis
of p16INK4a expression in LCLs established by using three
individual CtBP-binding motif mutant viruses for EBNA-3A, 3C
and for both -3A and -3C revealed that CtBP recruitment is
absolutely critical in the EBNA-3A and -3C-mediated epigenetic
repression of the p16INK4a promoter (Skalska et al., 2010).
However, interestingly no EBNA-3A or -3C/CtBP complexes
have been demonstrated on the p16INK4a promoter, there are
consistent reports that showed that the CtBP-binding motif is
typically essential for LCL growth maintenance using conditional
EBNA-3C-expressing LCLs and subsequent rescue studies (Lee
et al., 2009).
In contrast, a recent investigation using ChIP-Seq and ChIP-
qPCR techniques demonstrated that EBNA3-enriched sites were
specifically located in CtBP2 locus instead of CtBP1 locus
(McClellan et al., 2013). Interestingly, earlier results from
different group demonstrated that only CtBP2 expression is
negatively controlled by EBNA-3A (Hertle et al., 2009). However,
EBNA-3B and -3C had no effect on CtBP2 expression in
corresponding expression-deficient LCLs (White et al., 2010;
Skalska et al., 2013). In contrast to CtBP2, similar investigation
on CtBP1 expression demonstrated a relatively higher expression
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level in all EBV-infected cells irrespective of EBNA-3 expression
(White et al., 2010; Skalska et al., 2013), signifying a differential
regulation pattern of CtBP1 and CtBP2 in response to EBV
infection. Consistent with EBNA-3A mediated repression of
CtBP2 locus, it has been further demonstrated that only EBNA-
3A but not the other bound EBNA-3 proteins including EBNA-2
blocked chromatin looping of the enhancer sequence required for
transcriptional initiation (McClellan et al., 2013).
DP103/Gemin3 and Survival of Motor
Neurons (SMN) Protein—Possible Role in
RNA Processing
Gemin3 (also named as DDX20 or DP103), a member of
ATP-dependent RNA helicase family plays several important
roles in RNA metabolism (Yan et al., 2003; Fuller-Pace et al.,
2007). This family of proteins contain several conserved motifs
including the “ASP-Glu-Ala-Asp” or “DEAD box” motif (Yan
et al., 2003). The protein along with survival of motor neurons
(SMN) complex was initially identified as cellular interacting
partners of both EBNA-2 and EBNA-3C using a yeast-2 hybrid
screening (Grundhoff et al., 1999). The binding domain of EBNA-
3C was mapped within the C-terminal aa 534-778 (Grundhoff
et al., 1999). Gemin3 was shown to play a role in gene
transcription regulation, through interacting with a number of
cellular transcription factors including steroidogenic factor 1 (SF-
1), early growth response protein 2 (Egr2), forkhead transcription
factor FOXL2 and mitogen Ets repressor METS (Cai et al.,
2011; Saha and Robertson, 2013). However, the precise role
of Gemin3 in EBV transformed B-lymphocytes was still in
debate. Interestingly, Gemin3 was simultaneously identified as
a component of SMN complex, which plays an important role
in small nuclear ribonucleoproteins (snRNP) proteins assembly
(Grundhoff et al., 1999; Battle et al., 2006). The speckled fashion
of nuclear expression pattern of EBNA-3 proteins appeared
to be stable throughout the cell-cycle. GFP-tagged expression
constructs encoding EBNA-3C truncations identified aa 733-808
as the mediator of this nuclear localization pattern. Remarkably,
both EBNA-3C and EBNA-3A appeared to co-localize to
the identical granular structures, and subsequent analysis
demonstrated that EBNA-3C but not EBNA-3A associates with
SMN complex in these granules (Krauer K. et al., 2004; Krauer, K.
G. et al., 2004a), suggesting possible involvement of EBNA-3C in
RNA processing. However, to date no such phenomena has been
established for EBNA-3 proteins. Interestingly, a different role for
Gemin3 has recently been demonstrated in connection to EBNA-
3C mediated transcriptional activity. EBNA-3C induces Gemin3
accumulation in EBV-transformed primary B-lymphocytes and
stabilizes a complex formation with p53 tumor suppressor
where it acts as a negative regulator through attenuating p53
transcription and apoptotic activities (Cai et al., 2011).
EBNA-3 Proteins Target c-Myc
Transcriptional Activity In vitro
Both c-Myc translocation and EBV infection status concurrently
play critical roles in the development of Burkitt’s lymphoma (BL)
(Brady et al., 2007). Besides its direct role in transformation,
c-Myc can also promote double-stranded DNA breaks and
chromosomal aberrations and thereby inducing apoptosis
utilizing ATM/Chk2/p53 signaling cascade (Hoffman and
Liebermann, 2008). In general, BL expresses a restricted latency
I program with only EBNA-1 expression (Molyneux et al., 2012).
However, it has been suggested that a subset of in vitro generated
BL clones may retain the expression of EBNA-3 proteins in either
a Wp-restricted latency program with EBNA-2 deletion or a rare
EBNA-2(+)/LMP-1(−) latency associated program, indicating
the importance of EBNA-3 proteins, in particular EBNA-3A
and -3C, in regulating BL pathogenesis thorough blocking
cellular apoptosis (Kelly et al., 2005, 2006; Anderton et al.,
2008). While EBNA-2 accelerates c-Myc transcription, EBNA-
3A downregulates c-Myc expression through recruiting RBP-JK
activity (Kaiser et al., 1999; Cooper et al., 2003). Later, EBNA-
3C was independently shown to deregulate c-Myc transcription
in a luciferase based reporter assay using a c-Myc responsive
telomerase reverse transcriptase promoter (Bajaj et al., 2008).
In this study, EBNA-3C mediated c-Myc transactivation could
be influenced by either a direct protein-protein interaction
or enhancing its protein stability through blocking ubiquitin-
proteasomal degradation (Bajaj et al., 2008). Interestingly, the
EBNA-3C binding domain was mapped at the N-terminal region
flanking aa 130-190, responsible to recruit SCFSkp2 E3 ligase
activity (Bajaj et al., 2008). Since, c-Myc employs Skp2 as its
transcriptional cofactor (von der Lehr et al., 2003); it is tempting
to speculate that EBNA-3C may also alter its binding capacity
toward Skp2 in order to regulate c-Myc transcription. However,
as of now there is no direct evidence that confirms EBNA-3
mediated c-Myc deregulation in BL-biopsy samples.
Role of Chromatin Remodeling Factors in
EBNA-3 Mediated Transcriptional Activities
Using Chromatin immunoprecipition (ChIP) and ChIP-Seq
techniques, it is now known that EBNA-3 proteins either
individually or in group (particularly EBNA-3A and -3C
together) extensively modulate more than 1000 cellular genes
throughout the genome via recruiting chromatin remodeling
activities (Skalska et al., 2010; White et al., 2010; Allday et al.,
2015).
The idea has begun with an initial yeast-two hybrid study
with the C-terminal domain of EBNA-3C revealed an interaction
with a highly conserved histone H1 interacting protein,
prothymosin α (Pro-α), involved in cancer propagation through
chromatin remodeling and subsequently alter gene transcription
(Subramanian et al., 2002a; Ioannou et al., 2012). The Pro-
α binding domain of EBNA-3C was mapped within aa 366-
393. Interestingly, EBNA-3C was shown to compete with Pro-α
for binding with p300, a transcriptional activator with histone
acetyltransferase (HAT) activity (Subramanian et al., 2002a; Iyer
et al., 2004). Interestingly, both EBNA-3C and Pro-α were shown
to interact with p300 at two distinct sites including the CH1
N-terminal region and the bromodomain comprising of CH3
and HAT domains (Subramanian et al., 2002a). Two distinct
interacting domains of EBNA-3C were identified—one at the
N-terminal region containing both RBP-JK binding and bZIP
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domains, and the other at the C-terminal region containing
proline and glutamine rich domain required for transcriptional
activation. While Pro-α along with p300 activate transcription
using a GAL4 DNA binding domain fused promoter assay, the
overall activity is down-regulated in the presence of EBNA-3C
(Subramanian et al., 2002a).
EBNA-3Cwas also shown to interact with histone deacetylases
- both HDAC1 and HDAC2, suggesting an additional role in
transcriptional repression as addition of an HDAC inhibitor
rescued EBNA-3C mediated transcriptional suppression of viral
Cp promoter (Knight et al., 2003). Interestingly, the HDAC
binding domain of EBNA-3C was found to be overlapped with
RBP-JK interacting region spanning aa 1-211. Moreover, EBNA-
3C was shown to form stable transcription repression complex
containing mSin3A and NcoR1 directly interacting with Pro-α
(Knight et al., 2003). Overall, the results indicate that EBNA-
3C recruits HDAC activity embedded within a large protein
complex comprising several important transcription factors
including RBP-JK for transcriptional repression—such as from
Cp promoter.
In addition to modifying HAT and HDAC activities, EBNA-3
proteins precisely EBNA-3A and -3C were also shown to recruit
DNA-methyltransferase (DNMT) activity in order to suppress
Bim (BCL2L11) tumor suppressor expression in Burkitt’s
lymphoma cells (Anderton et al., 2008; Paschos et al., 2009)
(discussed in more details in later section). Later, ChIP analyses
demonstrated that EBV infection leads to the recruitment of
polycomb repressive complex (PRC)2 core subunits and the
trimethylation of histone H3 lysine 27 (H3K27me3) at the
Bim locus resulted in transcriptional repression. It has been
suggested that EBV infection is essential to recruit histone methyl
transferases both SUZ12 and EZH2 to establish functional PRC2.
Since formation of PRC2 complex at the Bim locus appeared to
be reliant on both EBNA-3A and -3C expression, It has been
suggested that EBNA-3 proteins might directly interact with
PRC2 (Paschos et al., 2012; McClellan et al., 2013; Jiang et al.,
2014). However, the precise molecular mechanism by which
EBV latent proteins recruit polycomb complexes to restrain Bim
expression is yet to be determined.
Both EBNA-3A and -3C were shown to downregulate
expression levels of multiple Cyclin dependent kinase inhibitors
(CDKI), such as p14ARF, p15INK4a, p16INK4a via epigenetic
regulation (Skalska et al., 2010, 2013). While suppression of
p16INK4a expression revealed to play a central role in EBV
induced B-cell transformation process (Maruo et al., 2006, 2011;
Skalska et al., 2010, 2013), precise roles of p15INK4b and p14ARF
in connection to the inhibition of B-cell transformation or
LCLs outgrowth, remain largely unclear. Using ChIP analyses
on genetically engineered LCLs expressing conditionally active
EBNA-3A and -3C, it has been clearly demonstrated that both
EBNA-3A and -3C repress p16INK4a expression by recruiting
a repressive H3K27me3 epigenetic mark on corresponding
CDKN2A locus (Skalska et al., 2010, 2013; Maruo et al.,
2011). In addition, recruitment of CtBP1 by EBNA-3A and -
3C were also shown to be important for efficient deposition of
H3K27me3 on p16INK4a gene locus for its repression (Skalska
et al., 2010). Similarly, EBNA-3A was shown to repress p15INK4a
gene (CDKN2B) transcription through recruiting MIZ1 and
H3K27me3 repressive histone modification (Bazot et al., 2014).
CELL-CYCLE REGULATION
EBNA-3 Proteins Extensively Modulate
Cell-Cycle Machinery
The role of the EBNA-3 proteins on cell-cycle regulation was
initially demonstrated using an EBV positive Burkitt’s lymphoma
derived cell line—Raji, where the EBNA-3C gene was deleted
(Allday et al., 1993; Allday and Farrell, 1994). Raji (1EBNA-
3C) cells at high density could be arrested in the G1 phase
of the cell-cycle, whereas the cell-cycle activity can be restored
by EBNA-3C expression (Allday and Farrell, 1994). Precisely,
EBNA-3C was shown to induce LMP-1 transcription and
pRb phosphorylation (Allday and Farrell, 1994). In agreement
with pRb hyperphosphorylation, EBNA-3C was also shown to
transactivate an E2F responsive promoter B-myb (Parker et al.,
1996). These results signified for the first time that one of the
EBNA-3 proteins might play a prominent role in G1-S phase
transition of the cell-cycle by targeting the putative pRb-E2F
complex. Similarly, EBNA-3C expression in NIH3T3 and U2OS
cells rescued the growth arrest at G1 phase caused by serum
starvation. Moreover, EBNA-3C was shown to downregulate
one of the cyclin dependent kinase inhibitor (CDKI) p27KIP1
expression and suppress the pro-metaphase arrest. Collectively,
results portrayed a model where EBNA-3C expression led to
a complete disruption of multiple cell-cycle checkpoints at
both G1/S and G2/M (Parker et al., 2000). In a series of
studies we and others have demonstrated that EBNA-3C can
physically interact with a number of important proteins involved
in cell-cycle regulation at both G1/S and G2/M checkpoints,
such as tumor suppressor proteins—pRb and p53, E3-ubiquitin
ligase—SCFSkp2, oncoproteins—c-Myc, cyclin A, cyclin D1, p53
regulatory proteins—Mdm2, ING4, and ING5, DNA damage
responder—E2F1, Chk2, H2AX, and Aurora kinase B among
many others (Jha et al., 2013, 2014; Saha and Robertson, 2013).
As earlier discussed that EBNA-3A and -3C but not -3B
are essential for B-cell transformation in vitro, it was still not
clear whether EBNA-3 proteins are important in maintaining
LCLs growth once transformed. Using LCLs with conditionally
expressed EBNA-3 proteins and trans-complementation assays
it has been clearly demonstrated both EBNA-3A and -3C are
indispensible for LCLs survival (Maruo et al., 2005, 2006). Using
this system it has been determined that EBNA-3C specifically
targeted CDK inhibitor p16INK4A (Maruo et al., 2011). Using
the similar conditional EBNA-3A and -3C expressing LCL
models, it has been further confirmed that RBP-JK binding
and CtBP motifs are important for maintaining LCL growth
(Maruo et al., 2005, 2009). In the similar study, it has been
suggested that the N-terminal residues EBNA-3C that have been
shown to recruit various important cell-cycle proteins—SCFSkp2,
pRb, p53, Mdm2, E2F1, Cyclin A, Cyclin D1 among others are
important for maintaining LCLs growth (Maruo et al., 2009). In
a recent report, EBNA-3A was shown to interact with a Myc-
interacting zinc-finger protein-1 (MIZ1) and that is required
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FIGURE 1 | Schematic represents multiple functions of the EBNA-3 family of proteins in developing EBV associated B-cell lymphomas.
for down-regulation of the CDK inhibitor p15INK4b in LCLs
(Bazot et al., 2014), suggesting a possible role in EBV-infected
B-cell proliferation. Taken together, it is seemingly evident that
both EBAN-3A and -3C proteins regulate B-cell transformation
and subsequently induce B-cell lymphoma development through
targeting major cell-cycle regulators including cyclin-cyclin
dependent kinase (CDK) complexes, CDK inhibitors (CDKI),
and checkpoint regulators (Figure 1).
EBNA-3C Interacts with All Major Cyclins
Cell-cycle progression is dependent on the activity of cyclins, a
family of proteins whose levels oscillate in synchrony with cell-
cycle progression, and its functional partner CDKs (Hochegger
et al., 2008). An initial yeast-two hybrid study using C-terminal
aa 890-992 of EBNA-3C revealed an interaction with Cyclin
A, which was subsequently confirmed by both in vitro and
in vivo binding experiments (Knight and Robertson, 2004).
EBNA-3C was also shown to block CDKI p27Kip1 actions on
Cyclin A/CDK2 regulated kinase activity, suggesting a potential
mechanism for facilitating G1/S transition of the cell-cycle
(Knight and Robertson, 2004). As CDK2 form complexes with
both Cyclin A and Cyclin E during the G1 to S phases of the
cell-cycle, it was further confirmed that the effect was specific for
Cyclin A, as co-expression of Cyclin E/CDK2 with EBNA-3C was
not able to retrieve p27-mediated inhibition. However, EBNA-3C
could physically interact with all the cyclins including Cyclin A,
D1 and E in an in vitro interaction study. Interestingly, although
the Cyclin A binding domain was initially mapped at extreme
C-terminal region amino acid residues 957-990, following studies
revealed a stronger interaction domain at the N-terminal
region amino acid residues 130-159, surrounding the conserved
homology domain of the EBNA-3 proteins (Knight et al., 2004).
Indeed, in an in vitro study EBNA-3B but surprisingly not
EBNA-3A demonstrated a modest binding activity (Knight et al.,
2004). In addition, the N-terminal binding domain of EBNA-
3C was appeared to be responsible for restricting p27Kip1-
mediated inhibition of Cyclin A/CDK2 kinasing activity, whereas
C-terminal binding domain perhaps plays as a stabilizing element
of this complex (Knight and Robertson, 2004; Knight et al., 2004).
In a recent work it has been shown that EBNA-3C can
form a stable complex with Cyclin D1/CDK6 in both stably
expressing as well as EBV-transformed B-cells. Whether
the interaction between EBNA-3C with different cyclins
is dependent on different cell-cycle stages and how these
interactions eventually trigger EBNA-3C mediated B-cell
transformation, is remain unexplored. It has been proposed
that Cyclin D proteins (D1, D2, and D3) besides initiating
cell-cycle at G1 phase, may have distinct biological activities
at specific steps of B-cell differentiation, and their expression
can be differentially regulated in response to EBV-infection
(Palmero et al., 1993; Saha et al., 2011b). Indeed, in contrast
to the previously published results, in vitro EBV infection
in primary B-lymphocytes along with EBV-positive BL
derived cell lines resulted in significant up-regulation of
all the D-type cyclins (Palmero et al., 1993; Saha et al.,
2011b, 2015). Elevation of Cyclin D1 protein level without
affecting its genetic structure, has been shown to be one
of the potential mechanisms for its deregulated activities
at G1-S phase transition of the cell-cycle (Musgrove et al.,
2011). Moreover, Cyclin D1 expression is strictly cell-cycle
dependent and its expression is regulated by both sub-cellular
localization and ubiquitin-targeted proteosomal machineries
(Musgrove et al., 2011). During G1-S transition of the cell-
cycle, Cyclin D1 appeared to be more nuclear localized
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with reduced proteolytic activity and inhibited GSK-3β
kinasing function which phosphorylates at T286 cyclin D1
leading to cycltoplasmic localization for ubiquitin-proteasome
mediated degradation (Alao, 2007; Musgrove et al., 2011).
Remarkably, EBNA-3C was shown to play a dual role that
leads to an increasing nuclear localization of Cyclin D1 by
blocking its poly-ubiquitination level assisted with inhibition
of GSK-3β mediated phosphorylation (Saha et al., 2011b).
Given that overexpression of Cyclin D1 is directly linked
to development of cancer development through integrating
the control of pRb phosphorylation with the transcriptional
activity of E2F transcription factors, targeting Cyclin D1
degradation would offer as a potential therapeutic mechanism
in EBV associated B-cell lymphomas, where EBNA-3C is
expressed.
Targeting pRb Provides a Best Possible
Link to Facilitate G1 to S Phase Transition
of the Cell-Cycle
As discussed earlier, the initial clue for a possible interaction
between EBNA-3C and pRb came from the observation that
ectopic EBNA-3C expression can rescue Raji cells arrested at G1
phase through increasing the pRb phosphorylation (Allday and
Farrell, 1994). In addition, EBNA-3C as similar to other tumor
virus encoded oncoproteins such as adenovirus E1A and HPV
E7 was shown to interact in vitro with pRb and regulate its
downstream activities through E2F transcription factors (Parker
et al., 1996). Moreover, all these viral oncoproteins contain a
pRb interactive motif LxCxE (Parker et al., 1996). This led
researchers to further investigate on both upstream regulators
such as CDK inhibitors and downstream effectors such as E2F
mediated transactivation process. Later, EBNA-3C was shown to
form a complex with pRb in cell (Knight et al., 2005a; Kashuba
et al., 2008), in which a mitochondrial ribosomal protein S18-2
(MRPS18-2) acts as a bridging protein between EBNA-3C and
pRb and plays an important role in deregulating its downstream
activities (Kashuba et al., 2008). Interestingly, the binding
between pRb and EBNA-3C was shown to be stabilized in the
presence of proteasomal inhibitor (Knight et al., 2005a), indicates
that EBNA-3Cmight also be involved in pRb degradation besides
regulating its phosphorylation status. Indeed, EBNA-3C was
shown to enhance pRb polyubiquitination through recruitment
of SCFSkp2 complex E3 ligase in an in vitro setting (Knight et al.,
2005a). The pRb interacting domain was mapped at aa 130-159,
where aa 140-149 was shown to be important for facilitating pRb
degradation (Knight et al., 2005a). In contrast, studies using LCLs
with conditionally active EBNA-3C expression, it has been shown
that EBNA-3C was not responsible for pRb degradation rather it
maintains a hyperphosphorylation status of pRb (Maruo et al.,
2006; Zhao et al., 2010). As noted earlier, EBNA-3C can enhance
the kinase activities of both G-phase cyclin–Cyclin D1/CDK6
and S-phase cyclin–Cyclin A/CDK2 complexes, which altogether
phosphorylate pRb (Knight et al., 2004; Saha et al., 2011b). It has
been suggested that EBNA-3C mediated phosphyrylation of pRb
act as a prerequisite for accelerating G1-S phase transition of the
cell-cycle.
Chk2: Effect of EBNA-3 Proteins at G2/M
Phase
In general, EBV-negative BL derived cell lines are more
susceptible to genotoxic agents in comparison to EBV positive
lines including LCLs and thereby experiencing cell-cycle arrest
at the G2/M checkpoint (Wade and Allday, 2000). In addition,
BL derived cell lines stably expressing individual EBNA-3 family
proteins but not EBNA-2 or EBNA-LP could also bypass cell-
cycle arrest at the G2/M checkpoint (Parker et al., 2000). This
led researchers to further study on plausible involvement of
ATM/ATR kinase family of proteins in G2/M arrest. In fact, in
two separate studies, both EBNA-3A and -3C were demonstrated
to form stable complexes with Chk2 protein, a downstream
checkpoint kinase of ATM mediated DNA damage response
pathway (Krauer K. G. et al., 2004b; Choudhuri et al., 2007). The
interaction between EBNA-3C and Chk2 eventually resulted in a
phosphorylation of Cdc25c at S216, which subsequently promotes
its own sequestration in the cytoplasm through interaction with
14-3-3 and in so doing allows the kinase activation of Cyclin
B/Cdc2 complex and helps in circumventing the G2/M block
induced by drug nocodazole (Choudhuri et al., 2007). This study
was the first attempt in order to demonstrate a underlying
mechanism by which EBNA-3C disrupts the G2/M checkpoint
signaling to maintain the continuous proliferation of EBV-
transformed B-cells (Choudhuri et al., 2007). In agreement with
this finding, a recent study also showed that EBNA-3C expression
is absolutely required to attenuate ATM-Chk2 mediated DNA
damage responsive signaling for B-cell transformation (Nikitin
et al., 2010; Li and Hayward, 2011).
INHIBITION OF APOPTOTIC MACHINERIES
Cancer cells sustain mutations in many important cellular
components that disrupt normal mechanisms controlling
proliferation. Remarkably, both pRb–E2F1 and Mdm2–p53
signaling network are found to be defective in most tumors,
emphasizing the central role of these cascades in regulating cell-
cycle progression. Two apoptotic pathways exist in mammals -
intrinsic and extrinsic, ultimately converge with the activation
of cysteine proteases named caspases (Elmore, 2007; Jendrossek,
2012). Interestingly, EBNA-3 proteins in particular EBNA-3Cwas
shown to extensively regulate many tumor suppressor proteins
via intrinsic apoptotic pathway (Figure 1).
EBNA-3C Regulates p53-Induced
Apoptosis by Multiple Mechanisms
The p53 tumor suppressor is perhaps represents one of the most
important drug targets in cancer therapy as the corresponding
gene has been found to be mutated or deleted in half of all
malignant tumors, whereas the other half express wild-type p53
and in one way or another is functionally blocked (Essmann and
Schulze-Osthoff, 2012; Mirzayans et al., 2012). As similar to pRb,
tumor viruses have evolved multiple strategies to inhibit directly
p53 functions or its upstream or downstream effectors are being
inactivated indirectly affecting p53 mediated transcriptional as
well as apoptotic activities (Saha et al., 2010). As similar to
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many other tumor virus encoded antigens, EBNA-3C was also
shown to attenuate p53-induced apoptosis employing multiple
mechanisms (Saha and Robertson, 2013). EBNA-3C forms a
complex with p53 and the interacting domain was mapped near
the N-terminal region comprising aa 130-190 (Yi et al., 2009).
Interestingly, these binding residues, as described in the earlier
section, have been previously shown to interact with several
other important cell-cycle proteins, such as SCFSkp2, pRb, c-
Myc, Cyclin A, Cyclin E, Cyclin D1, and RBP-Jκ, signifying its
critical involvement in cell-cycle deregulation (Robertson et al.,
1996; Knight et al., 2005a,b; Bajaj et al., 2008; Saha et al., 2011b;
Saha and Robertson, 2013). Additionally, genetic study using
recombinant EBV virus expressing conditionally active EBNA-
3C revealed that absence of this particular domain was unable
to maintain LCLs growth (Maruo et al., 2009). Importantly,
EBNA-3C interacts with p53 with its central DNA-binding
and C-terminal oligomerization domains (Yi et al., 2009),
providing clues that EBNA-3C might regulate its transcription
activities. Indeed, reporter assays using p53 responsive promoter
element demonstrated that EBNA-3C appreciably inhibits p53
transactivation and subsequent apoptotic activities (Yi et al.,
2009). Since p53 regulated transcription can be modulated by
several means, it has been speculated that EBNA-3C could
employ other potential mechanisms.
In order to investigate other potential mechanisms by which
EBNA-3C could affect p53 mediated transcription and as a result
apoptotic regulation, EBNA-3C was shown to interact with p53
modulators ING4 and ING5 belong to ING (inhibitor of growth)
family (Saha et al., 2011a). The best known function of ING
proteins, whose expression was shown to be significantly reduced
in many cancer types, is their cooperation with p53 in tumor
suppression (Russell et al., 2006; Jafarnejad and Li, 2011). EBNA-
3C interacts with both ING4 and ING5 in a p53 independent
manner as binding studies were performed in p53 positive in vitro
EBV transformed LCLs, EBNA-3C stably expressing BL derived
cell line BJAB where p53 is genetically defective and ectopic
expression systems in Saos-2 where p53 is deleted (Saha et al.,
2011a). However, the binding region of EBNA-3C was shown
to be overlapped with p53 interacting site at the N-terminal
region covering aa 129-200 (Saha et al., 2011a), suggesting
that interaction with ING-proteins may influence its binding
affinity toward p53. In fact, increasing dose of p53 concentration
appreciably impeded the complex formation between EBNA-
3C with ING proteins (Saha et al., 2011a). Additionally, the
binding domains for both EBNA-3C and p53 were mapped at
the identical residues of ING proteins—comprising the bipartite
nuclear localization domain (NLS1 and NLS2) of ING4 and
the conserved PHD domain of ING5 (Saha et al., 2011a). The
PHD domain through recruiting HAT and HDAC activities
represents as a central structural identity of ING proteins
(Russell et al., 2006). However, whether EBNA-3C and/or p53
modulate its chromatin remodeling functions remains unclear.
Similarly the interaction of ING4 NLS domain with EBNA-3C
and p53 affects its sub-cellular localization is still speculative.
Nonetheless, EBNA-3C substantially antagonizes ING4 and
ING5 promoted p53mediated ant-proliferative activities possibly
through blocking the interaction of ING proteins with p53 (Saha
et al., 2011a) and thus restoration of ING functions in order
to activate p53 induced apoptosis offers a potential therapeutic
approach against EBV associated B-cell lymphomas.
The ubiquitin-mediated proteasomal degradation of p53 by
Mdm2, one of its many negative regulators, symbolizes as
one of the most important regulations in p53 mediated tumor
suppressive activities (Di et al., 2011; Essmann and Schulze-
Osthoff, 2012). It has been shown that in vitro EBV transformed
LCLs expressing wild-type p53 are sensitive to Nutlin-3a
mediated growth suppression, which exclusively targets p53-
Mdm2 interaction and thereby increasing p53 stability and
apoptosis (Forte and Luftig, 2009). In parallel with this finding,
EBNA-3C was shown to recruit Mdm2 E3 ligase activity in
order to facilitate p53 degradation (Saha et al., 2009). As
discussed earlier, EBNA-3C efficiently deregulates the ubiquitin-
proteasome machinery and that profoundly affects stability of
many tumor suppressor proteins—p27Kip1 and pRb through
enhancing their degradation as well as increases the stability
of products of several proto-oncogenes such as Cyclin D1
and c-Myc (Knight et al., 2005a,b; Bajaj et al., 2008; Saha
et al., 2011b). In this study, the authors evidently demonstrated
that other than regulating its own polyubiquitination, EBNA-
3C can also obstruct Mdm2-ployubiquitination and thereby
increasing its stability as similar to Cyclin D1 and c-Myc
(Bajaj et al., 2008; Saha et al., 2009, 2011b). In addition to
negatively affecting p53 transcription and apoptotic activity,
Mdm2 can also deregulate apoptotic function of pRb and E2F1,
which were also shown to interact with EBNA-3C (Knight
et al., 2005a; Polager and Ginsberg, 2009; Saha et al., 2012).
However, so far there is no direct evidence that shows EBNA-
3C recruits Mdm2 activity in order to control the pRb-
E2F1 arm at the G1-S phase of the cell-cycle. Interestingly,
EBNA-3C utilizes the similar N-terminal domain comprising
aa 130-190 formerly identified as interacting region of many
important cell-cycle regulators including p53, in order to
recruit Mdm2 E3 ligase activity toward p53 degradation (Saha
et al., 2009). In addition, the central acidic domain of Mdm2
was shown to be responsible for interaction with EBNA-3C
(Saha et al., 2009). Interestingly, a number of earlier studies
revealed that this central acidic domain plays an important
role in regulating Mdm2 mediated E3 ligase activity toward
p53 degradation through interacting with many positive such
as p14ARF and pRb as well as negative regulators including
p300 (Kawai et al., 2003). Collectively, this study along with
the study with Nutlin-3a implicated a potential therapeutic
mechanism through targeting p53-Mdm2 complex against many
EBV associated B-cell lymphomas expressing functionally
active p53.
As discussed in the previous section, the interaction
between EBNA-3C and DP103/Gemin3 (belongs to DEAD-box
RNA helicase family) has been implicated in p53 mediated
transcriptional as well as apoptotic activities (Yan et al., 2003;
Cai et al., 2011). In agreement with previously described
EBNA-3C regulated p53 activities, this work further appended
as a potential mechanism through which p53 is deregulated
in EBV associated B-cell lymphomas. Although Gemin3 has
previously been characterized as a transcriptional repressor, the
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precise mechanism by which Gemin3 regulates transcriptional
activity is not completely known beside its role in RNA
metabolism (Yan et al., 2003). Since, Gemin3 through recruiting
HDAC and sumo activities represses transcriptional activation,
it has been suggested that EBNA-3C/Gemin3 complex can also
alter p53-dependent anti-proliferative activities by affecting its
acetylation and sumoylation status. Given that the critical role
of Gemin3 in cancer development, prompted us to speculate
that high throughput screening of helicase inhibitors would
result in prospective therapeutic strategy against EBV associated
B-cell lymphomas possibly through initiating p53 regulated
apoptosis.
In a recent study, EBNA-3C was additionally shown to
block p53 expression and subsequent transcription and apoptotic
activities through stabilizing and recruiting Aurora kinase B
mediated kinase activity (Jha et al., 2013, 2015).
EBNA-3C Antagonizes E2F1-Regulated
Apoptosis in Response to DNA Damage
Signals
As discussed in earlier sections, EBNA-3C targets a number of
upstream components of the E2F1 signaling pathway involved
in cell-cycle, DNA repair, differentiation as well as apoptosis
in both p53 dependent and independent manner (Krauer K.
G. et al., 2004b; Knight et al., 2005a; Saha et al., 2011b). The
interaction between EBNA-3C and pRb led further investigation
to determine whether EBNA-3C can also form a complex with
its downstream regulator, E2F1 and thereby facilitating the G1-
S transition of the cell-cycle. Indeed, EBNA-3C was shown
to physically interact with E2F1 (Saha et al., 2012), however
in a pRb independent manner, suggesting that EBNA-3C may
regulate E2F1 activity through a different mechanism. Since
p53 has been found to be mutated or functionally deactivated
in most of the cancers, targeting E2F1-mediated apoptosis in
response to DNA damage signals can provide as an additional
therapeutic means (Polager and Ginsberg, 2009; Wu and Yu,
2009). In accordance with this notion, EBNA-3C was shown to
inhibit E2F1 dependent apoptotic activities through targeting its
downstream apoptotic regulators such as p73 and Apaf-1 in EBV
positive B-cells (Saha et al., 2012). In this connection, another
group has recently shown that EBNA-3C forms a stable complex
with p73 and blocks doxirubicin induced p73 mediated apoptosis
(Sahu et al., 2014). The N-terminal DNA binding domain of E2F1
aa 1-243, liable to apoptotic regulation, binds to two discrete
regions of EBNA-3C, positioned at N-terminal aa 100-200 and
C-terminal aa 621-700 (Saha et al., 2012). Importantly, while the
N-terminal binding domain of EBNA-3C previously shown to
interact with many other cell-cycle proteins as discussed earlier
directly interacts with E2F1, the C-terminal region requires
unidentified cellular protein(s) to form a complex with E2F1
(Saha et al., 2012). Moreover, using trans-complementation
assay in LCLs expressing conditionally active EBNA-3C, this
N-terminal binding domain but not the C-terminal region of
EBNA-3C was shown to be critical in maintaining LCLs growth
(Maruo et al., 2009). Another group demonstrated that EBNA-
3C is absolutely essential in attenuating DNA damage response
induced during early stage of viral infection of primary B-
lymphocytes in order to facilitate B-cell transformation (Nikitin
et al., 2010). In harmony with this finding, EBNA-3C knockout
EBV was also shown to be lacking its ability in restraining
E2F1 mediated DNA damage response during the early stages
of infection of nascent B-cells (Saha et al., 2012). As similar to
p53, DNA damage signals led to an induction and stabilization
of E2F1 expression, where both ubiquitin-tagged proteasomal
degradation and dissociation from pRb at G1-S phase of the cell-
cycle play important roles (Wu and Yu, 2009). Since SCFSkp2 as
one of the many E3 ligases involved in E2F1 degradation (Harper
and Elledge, 1999), it is tempting to speculate that EBNA-3Cmay
also recruit this E3 ligase activity for regulating E2F1 stability
and thus transcription. Although it remains elusive that whether
EBNA-3C specifically employs SCFSkp2 E3 ligase activity, EBNA-
3C accelerates E2F1 degradation in an ubiquitin-proteasome
dependent manner (Saha et al., 2012). In addition, DNA damage
sensor components such as ATM-Chk2 and ATR-Chk1 stabilize
E2F1 expression through phosphorylation and thereby regulating
E2F1 mediated apoptotic signaling cascade (Wu and Yu, 2009).
As previously discussed EBNA-3C mediated deregulation of
ATM-Chk2 cascade demands further investigation in controlling
E2F1-targeted apoptosis in the context of EBV associated B-cell
lymphomas. Overall, these findings suggest E2F1 as a potential
therapeutic target regardless of p53 functional status against
several EBV associated B-cell lymphomas.
EBNA-3A and -3C Regulate Bim-Mediated
Apoptosis through Epigenetic Regulation
The tumor suppressor protein Bim or BCL2L11 represents one
of the crucial members of Bcl-2 (B-cell lymphoma 2) family
that induces apoptosis (Hughes et al., 2006). Bim plays an
important role during B-cell lymphomagenesis as deletion of
even a single allele can radically increase B-cell lymphoma
development in Eµ-Myc transgenic mice with constitutive c-
Myc expression within B-cells (Egle et al., 2004; Richter-Larrea
et al., 2010). As earlier discussed deregulation of c-Myc activity
due to chromosomal translocations is a characteristic feature
of Burkitt’s lymphoma (BL) and interestingly, Bim regulated
apoptosis was also shown to be coupled with c-Myc deregulation
that ultimately helps in developing B-cell lymphoma (Richter-
Larrea et al., 2010). Analysis of EBV latent gene expression
patterns in different EBV-positive BL derived cell lines revealed
that the EBNA-3 proteins might play an important role in
regulating Bim mediated apoptosis. Indeed, using genetically
engineered EBV, lacking individual EBNA-3 ORFs, EBNA-3A
and -3C but not -3B blocked Bimmediated apoptosis in response
to multiple cytotoxic drugs in a BL derived cell line, providing
a possible explanation by which EBV contributes to BL-
pathogenesis (Anderton et al., 2008). In addition, Bim expression
was drastically increased in response to both EBNA-3A and -3C
knockout viruses in contrast to cells infected with either wild-
type or mutant virus lacking expression of other EBNA genes
including EBNA-3B (Anderton et al., 2008). The suppression of
Bim expression in EBV positive B-cells by EBNA-3 proteins was
established at transcriptional level via epigenetic modification
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as treatment with HDAC and DNA-methyltransferase enzymes
(DNMT) inhibitors enhanced Bim expression (Anderton et al.,
2008). Epigenetic regulations including hypermethylation of
cytosine residue at CpG islands and covalent modifications
most prominently methylation and acetylation to the N-terminal
tails of histones, regulate gene expression through varying the
chromatin structure in a heritable manner and thus characterized
as a hallmark of cancer development (Bártová et al., 2008;
Sandoval and Esteller, 2012). As discussed in the earlier section,
EBNA-3C can recruit many chromatin modification enzymes
in order to regulate gene transcription (Radkov et al., 1999;
Cotter and Robertson, 2000; Knight et al., 2003; Skalska
et al., 2010). However, whether EBNA-3A or -3C may also
recruit DNMT activity, which is a common mechanism for
silencing transcriptional activation of many tumor suppressor
genes in most cancers, are unknown. Nevertheless, it has been
proposed that EBNA-3A and -3C repress Bim expression and
subsequently its apoptosis in BL through histone modification
H3K27-Me3 (trimethylation of histone H3 lysine 27) and CpG
hypermethylation at the Bim promoter (Paschos et al., 2009).
Interestingly, recently using a PCRmicroarray its has been shown
that EBV infection in primary B-lymphocytes led to a global
transcriptional repression of an array of tumor suppressor genes
through recruiting hypermethylation activity (Saha et al., 2015),
suggesting a commonmechanism by which EBV promotes B-cell
immortalization.
ROLE IN METASTASIS
EBNA-3C Regulates Nm23-H1 Mediated
Anti-Metastatic Activities
Nm23-H1 belongs to nucleoside diphosphate kinases (NDPKs)
family, was identified as the first anti-metastatic protein
significantly implicated in cancer progression through regulating
various signaling pathways (Murakami et al., 2009; Marshall
et al., 2010). However there are many conflicting data, an altered
Nm23-H1 expression, both at protein and RNA levels coupled
with its metastatic activity was shown to directly associate
with many cancer types, including tumor virus associated B-
cell lymphomas (Marshall et al., 2010; Saha and Robertson,
2011b). Undoubtedly, EBNA-3C represents as one of the best
studied Nm23-H1 interacting partners, which was initially
identified in a yeast two hybrid screening (Subramanian et al.,
2001; Saha and Robertson, 2011b). Using series of truncated
EBNA-3C regions in both in vitro and in vivo settings, the
binding site was mapped at aa 657-675 (Subramanian and
Robertson, 2002). The interaction of EBNA-3C with Nm23-
H1 resulted in salvaging Nm23-H1 induced anti-proliferative
effects on cell migration examined in multiple cell lines
(Subramanian and Robertson, 2002). Contradictorily, EBNA-3C
can also accelerate Nm23-H1 mediated transcriptional activity
on multiple promoters - Cox-2, αv-integrin and MMP-9 (Saha
and Robertson, 2011b). Remarkably, EBNA-3C co-expression
leads to relocation of Nm23-H1’s cytoplasmic signal to mostly
nucleus, providing a possible explanation of enhanced Nm23-H1
mediated transcriptional activity (Subramanian et al., 2001; Saha
and Robertson, 2011b). However, how these changes eventually
influence Nm23-H1’s anti-metastatic activities is not clear. In
this context, an in vivo study using nude mice as model
system was conducted to determine the magnitude of EBNA-
3C’s ability in suppressing Nm23-H1 mediated anti-metastatic
potential (Kaul et al., 2007). The study demonstrated that EBNA-
3C significantly inhibits Nm23-H1 activity and induces the
initial tumor formation, while at the later stage both EBNA-
3C and Nm23-H1 seemed to have no function regarding tumor
progression (Kaul et al., 2007). This study also corroborated with
a previous study aimed to analyze Nm23-H1 expression levels in
established EBV-positive and negative B-cells with no apparent
change, indicating that Nm23-H1 might not be important once
the cancer has already developed (Murakami et al., 2009; Saha
and Robertson, 2011b). Since genetically engineered EBV lacking
EBNA-3C ORF is unable to transform primary B-lymphocytes,
EBNA-3C may regulate Nm23-H1 activities at early stage of
infection. In fact, a recent study using a PCR microarray showed
that EBV infection in nascent peripheral B-lymphocytes led to an
increased hypermethylation pattern of Nm23-H1 promoter and
thereby affecting its transcription (Saha et al., 2015). However,
whether EBAN-3C has any direct role in Nm23-H1 promoter
hypermethylation and subsequently expression level is currently
under investigation.
Blast analysis of the Nm23-H1 binding residues of EBNA-
3C revealed a considerable sequence homology with another
metastasis suppressor Necdin, a member of the melanoma-
associated antigen (MAGE) family of proteins comprising of
more than 60 genes that share the highly conserved MAGE
homology domain (MHD) (Kaul et al., 2009). Necdin acts as
a transcriptional repressor either by directly bind to the DNA
or through its interaction with major transcription regulators
such as p53, E2F1, and Hif-1α (Matsumoto et al., 2001).
Notably, elevated CpG-methylation of Necdin promoter in
EBV transformed B-lymphocytes was observed as compared to
nascent B-lymphocytes, suggesting that EBV latent antigens may
regulate Necdin expression and subsequently its function (Kaul
et al., 2009). In addition, Necdin expression level was shown
to be particularly lower in EBV-positive BL cells than that of
negative counterpart, further suggesting epigenetic regulation
might play an important role in Necdin expression in EBV
positive B-cells (Kaul et al., 2009). However, whether EBNA-3C
or any other EBV latent antigens recruit epigenetic machineries
in order to control Necdin expression is yet to be known.
On the other hand, EBNA-3C coupled with Nm23-H1 was
shown to deregulate Necdin mediated growth suppression and
anti-angiogenic property possibly through affecting at both
transcriptional and subcellular localization levels (Kaul et al.,
2009; Saha and Robertson, 2011b). Overall, this study suggests
a novel role for Necdin in regulating virus-associated human
cancers development.
CONCLUSION
Over the last decade a significant progress has been made toward
our understanding of how the EBNA-3 proteins contribute to
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the induction and subsequently development of several B-cell
lymphomas particularly in an immune-compromised scenario.
EBNA-3 proteins—particularly EBNA-3A and -3C deregulate a
number of cellular pathways including cell-cycle, apoptosis, and
metastasis largely through direct protein-protein interaction.
EBNA-3C, in particular regulates an array of cellular protein
level through manipulating ubiquitin-targeted proteasomal
machinery. In addition, both EBNA-3A and -3C deregulate
gene transcription through recruiting several chromatin
remodeling factors. Newer technological advancements such as
genetically modified viruses, microarray based techniques, and
whole transcriptomic analyses have essentially demonstrated
that these proteins play a major role in EBV induced B-
cell lymphomagenesis and therefore may facilitate in the
development of targeted therapeutics in near future.
AUTHOR CONTRIBUTIONS
SB, SG, PB and AS together wrote the paper. AS conceived the
idea and finally edited the manuscript.
ACKNOWLEDGMENTS
The authors apologize to colleagues whose research could
not be cited due to space constraint. The work in the AS’s
laboratory is supported by Wellcome Trust/DBT India Alliance
Intermediate Fellowship research grant (IA/I/14/2/501537),
Department of Biotechnology (DBT), Govt. of India
(BT/PR8123/MED/30/990/2013), and the FRPDF program
at Presidency University, Kolkata. SB is a DST-Inspire, Govt. of
India fellow (140626).
REFERENCES
Alao, J. P. (2007). The regulation of cyclin D1 degradation: roles in cancer
development and the potential for therapeutic invention. Mol. Cancer 6, 24.
doi: 10.1186/1476-4598-6-24
Allday, M. J., Bazot, Q., and White, R. E. (2015). The EBNA3 family: two
oncoproteins and a tumour suppressor that are central to the biology of EBV in
B Cells. Curr. Top. Microbiol. Immunol. 391, 61–117. doi: 10.1007/978-3-319-
22834-1_3
Allday, M. J., Crawford, D. H., and Thomas, J. A. (1993). Epstein-Barr virus (EBV)
nuclear antigen 6 induces expression of the EBV latent membrane protein
and an activated phenotype in Raji cells. J. Gen. Virol. 74(Pt 3), 361–369. doi:
10.1099/0022-1317-74-3-361
Allday, M. J., and Farrell, P. J. (1994). Epstein-Barr virus nuclear antigen
EBNA3C/6 expression maintains the level of latent membrane protein 1 in
G1-arrested cells. J. Virol. 68, 3491–3498.
Amoutzias, G. D., Veron, A. S., Weiner, III, Robinson-Rechavi, M., Bornberg-
Bauer, E., Oliver, S., et al. (2007). One billion years of bZIP transcription factor
evolution: conservation and change in dimerization and DNA-binding site
specificity.Mol. Biol. Evol. 24, 827–835. doi: 10.1093/molbev/msl211
Anderton, E., Yee, J., Smith, P., Crook, T., White, R. E., and Allday, M. J. (2008).
Two Epstein-Barr virus (EBV) oncoproteins cooperate to repress expression of
the proapoptotic tumour-suppressor Bim: clues to the pathogenesis of Burkitt’s
lymphoma. Oncogene 27, 421–433. doi: 10.1038/sj.onc.1210668
Bajaj, B. G., Murakami, M., Cai, Q., Verma, S. C., Lan, K., and Robertson,
E. S. (2008). Epstein-Barr virus nuclear antigen 3C interacts with and
enhances the stability of the c-Myc oncoprotein. J. Virol. 82, 4082–4090. doi:
10.1128/JVI.02500-07
Banerjee, S., Lu, J., Cai, Q., Saha, A., Jha, H. C., Robertson, E. S., et al. (2013).
The EBV Latent Antigen 3C inhibits apoptosis through targeted regulation
of interferon regulatory factors 4 and 8. PLoS Pathog. 9:e1003314. doi:
10.1371/journal.ppat.1003314
Bártová, E., Krejcí, J., Harnicarová, A., Galiova, G., and Kozubek, S. (2008). Histone
modifications and nuclear architecture: a review. J. Histochem. Cytochem. 56,
711–721. doi: 10.1369/jhc.2008.951251
Battle, D. J., Kasim, M., Yong, J., Lotti, F., Lau, C. K., Dreyfuss, G., et al. (2006).
The SMN complex: an assembly machine for RNPs. Cold Spring Harb. Symp.
Quant. Biol. 71, 313–320. doi: 10.1101/sqb.2006.71.001
Bazot, Q., Deschamps, T., Tafforeau, L., Siouda, M., Leblanc, P., Harth-Hertle, M.,
et al. (2014). Epstein-Barr virus nuclear antigen 3A protein regulates CDKN2B
transcription via interaction with MIZ-1.Nucleic Acids Res. 42, 9700–9716. doi:
10.1093/nar/gku697
Bourillot, P. Y., Waltzer, L., Sergeant, A., and Manet, E. (1998). Transcriptional
repression by the Epstein-Barr virus EBNA3A protein tethered to DNA does
not require RBP-Jkappa. J. Gen. Virol. 79(Pt 2), 363–370. doi: 10.1099/0022-
1317-79-2-363
Brady, G., MacArthur, G. J., and Farrell, P. J. (2007). Epstein-Barr virus and Burkitt
lymphoma. J. Clin. Pathol. 60, 1397–1402. doi: 10.1136/jcp.2007.047977
Buck, M., Burgess, A., Stirzaker, R., Krauer, K., and Sculley, T. (2006). Epstein-Barr
virus nuclear antigen 3A contains six nuclear-localization signals. J. Gen. Virol.
87, 2879–2884. doi: 10.1099/vir.0.81927-0
Burgess, A., Buck, M., Krauer, K., and Sculley, T. (2006). Nuclear localization
of the Epstein-Barr virus EBNA3B protein. J. Gen. Virol. 87, 789–793. doi:
10.1099/vir.0.81640-0
Cai, Q., Guo, Y., Xiao, B., Banerjee, S., Saha, A., Lu, J., et al. (2011).
Epstein-Barr virus nuclear antigen 3C stabilizes Gemin3 to block p53-
mediated apoptosis. PLoS Pathog. 7:e1002418. doi: 10.1371/journal.ppat.10
02418
Calderwood, M. A., Lee, S., Holthaus, A. M., Blacklow, S. C., Kieff, E., and
Johannsen, E. (2011). Epstein-Barr virus nuclear protein 3C binds to the N-
terminal (NTD) and beta trefoil domains (BTD) of RBP/CSL; only the NTD
interaction is essential for lymphoblastoid cell growth.Virology 414, 19–25. doi:
10.1016/j.virol.2011.02.018
Chen, A., Divisconte, M., Jiang, X., Quink, C., and Wang, F. (2005). Epstein-Barr
virus with the latent infection nuclear antigen 3B completely deleted is still
competent for B-cell growth transformation in vitro. J. Virol. 79, 4506–4509.
doi: 10.1128/JVI.79.7.4506-4509.2005
Chinnadurai, G. (2002). CtBP, an unconventional transcriptional corepressor
in development and oncogenesis. Mol. Cell 9, 213–224. doi: 10.1016/S1097-
2765(02)00443-4
Chinnadurai, G. (2009). The transcriptional corepressor CtBP: a foe of multiple
tumor suppressors. Cancer Res. 69, 731–734. doi: 10.1158/0008-5472.CAN-08-
3349
Choudhuri, T., Verma, S. C., Lan, K., Murakami, M., and Robertson, E. S. (2007).
The ATM/ATR signaling effector Chk2 is targeted by Epstein-Barr virus nuclear
antigen 3C to release the G2/M cell cycle block. J. Virol. 81, 6718–6730. doi:
10.1128/JVI.00053-07
Cludts, I., and Farrell, P. J. (1998). Multiple functions within the Epstein-Barr virus
EBNA-3A protein. J. Virol. 72, 1862–1869.
Cooper, A., Johannsen, E., Maruo, S. E., Cahir-McFarland, Illanes,
D., Davidson, D., et al. (2003). EBNA3A association with RBP-
Jkappa down-regulates c-myc and Epstein-Barr virus-transformed
lymphoblast growth. J. Virol. 77, 999–1010. doi: 10.1128/JVI.77.2.999-10
10.2003
Cotter, M. A. II, and Robertson, E. S. (2000). Modulation of histone
acetyltransferase activity through interaction of epstein-barr nuclear
antigen 3C with prothymosin alpha. Mol. Cell. Biol. 20, 5722–5735. doi:
10.1128/MCB.20.15.5722-5735.2000
Di, J., Zhang, Y., and Zheng, J. (2011). Reactivation of p53 by inhibiting Mdm2 E3
ligase: a novel antitumor approach. Curr. Cancer Drug Targets 11, 987–994. doi:
10.2174/156800911797264789
Egle, A., Harris, A.W., Bouillet, P., and Cory, S. (2004). Bim is a suppressor ofMyc-
induced mouse B cell leukemia. Proc. Natl. Acad. Sci. U.S.A. 101, 6164–6169.
doi: 10.1073/pnas.0401471101
Elmore, S. (2007). Apoptosis: a review of programmed cell death. Toxicol. Pathol.
35, 495–516. doi: 10.1080/01926230701320337
Frontiers in Microbiology | www.frontiersin.org 13 April 2016 | Volume 7 | Article 457
Bhattacharjee et al. EBNA-3 Proteins in EBV-Linked Lymphomas
Essmann, F., and Schulze-Osthoff, K. (2012). Translational approaches targeting
the p53 pathway for anti-cancer therapy. Br. J. Pharmacol. 165, 328–344. doi:
10.1111/j.1476-5381.2011.01570.x
Forte, E., and Luftig, M. A. (2009). MDM2-dependent inhibition of p53 is required
for Epstein-Barr virus B-cell growth transformation and infected-cell survival.
J. Virol. 83, 2491–2499. doi: 10.1128/JVI.01681-08
Fuller-Pace, F. V., Jacobs, A. M., and Nicol, S. M. (2007). Modulation of
transcriptional activity of the DEAD-box family of RNA helicases, p68
(Ddx5) and DP103 (Ddx20), by SUMO modification. Biochem. Soc. Trans. 35,
1427–1429. doi: 10.1042/BST0351427
Garrido, J. L., Maruo, S., Takada, K., and Rosendorff, A. (2009). EBNA3C interacts
with Gadd34 and counteracts the unfolded protein response.Virol. J. 6:231. doi:
10.1186/1743-422X-6-231
Grundhoff, A. T., Kremmer, E., Tureci, O., Glieden, A., Gindorf, C., Atz, J., et al.
(1999). Characterization of DP103, a novel DEAD box protein that binds to the
Epstein-Barr virus nuclear proteins EBNA2 and EBNA3C. J. Biol. Chem. 274,
19136–19144. doi: 10.1074/jbc.274.27.19136
Harper, J. W., and Elledge, S. J. (1999). Skipping into the E2F1-destruction
pathway. Nat. Cell Biol. 1, E5–E7. doi: 10.1038/8952
Hennessy, K., Fennewald, S., and Kieff, E. (1985). A third viral nuclear protein in
lymphoblasts immortalized by Epstein-Barr virus. Proc. Natl. Acad. Sci. U.S.A.
82, 5944–5948. doi: 10.1073/pnas.82.17.5944
Hennessy, K., Wang, F., Bushman, E. W., and Kieff, E. (1986). Definitive
identification of a member of the Epstein-Barr virus nuclear protein 3 family.
Proc. Natl. Acad. Sci. U.S.A. 83, 5693–5697. doi: 10.1073/pnas.83.15.5693
Hertle, M. L., Popp, C., Petermann, S., Maier, S., Kremmer, E., Lang, R.,
et al. (2009). Differential gene expression patterns of EBV infected EBNA-3A
positive and negative human B lymphocytes. PLoS Pathog. 5:e1000506. doi:
10.1371/journal.ppat.1000506
Hickabottom, M., Parker, G. A., Freemont, P., Crook, T., and Allday, M. J. (2002).
Two nonconsensus sites in the Epstein-Barr virus oncoprotein EBNA3A
cooperate to bind the co-repressor carboxyl-terminal-binding protein (CtBP).
J. Biol. Chem. 277, 47197–47204. doi: 10.1074/jbc.M208116200
Hochegger, H., Takeda, S., and Hunt, T. (2008). Cyclin-dependent kinases and
cell-cycle transitions: does one fit all? Nat. Rev. Mol. Cell Biol. 9, 910–916. doi:
10.1038/nrm2510
Hoffman, B., and Liebermann, D. A. (2008). Apoptotic signaling by c-MYC.
Oncogene 27, 6462–6472. doi: 10.1038/onc.2008.312
Hughes, P., Bouillet, P., and Strasser, A. (2006). Role of Bim and other Bcl-2 family
members in autoimmune and degenerative diseases. Curr. Dir. Autoimmun. 9,
74–94. doi: 10.1159/000090773
Ioannou, K., Samara, P., Livaniou, E., Derhovanessian, E., and Tsitsilonis, O. E.
(2012). Prothymosin alpha: a ubiquitous polypeptide with potential use in
cancer diagnosis and therapy. Cancer Immunol. Immunother. 61, 599–614. doi:
10.1007/s00262-012-1222-8
Iyer, N. G., Ozdag, H., and Caldas, C. (2004). p300/CBP and cancer. Oncogene 23,
4225–4231. doi: 10.1038/sj.onc.1207118
Jafarnejad, S. M., and Li, G. (2011). Regulation of p53 by ING family members
in suppression of tumor initiation and progression. Cancer Metastasis Rev. 31,
55–73. doi: 10.1007/s10555-011-9329-5
Jendrossek, V. (2012). The intrinsic apoptosis pathways as a target in
anticancer therapy. Curr. Pharm. Biotechnol. 13, 1426–1438. doi:
10.2174/138920112800784989
Jha, H. C., Lu, J., Saha, A., Cai, Q., Banerjee, S., Prasad, M., et al. (2013).
EBNA3C-mediated regulation of aurora kinase B contributes to Epstein-Barr
virus-induced B-cell proliferation through modulation of the activities of the
retinoblastoma protein and apoptotic caspases. J. Virol. 87, 12121–12138. doi:
10.1128/JVI.02379-13
Jha, H. C., Aj, M., Saha, A., Banerjee, S., Lu, J., and Robertson, E. S. (2014). Epstein-
Barr virus essential antigen EBNA3C attenuates H2AX expression. J. Virol. 88,
3776–3788. doi: 10.1128/JVI.03568-13
Jha, H. C., Yang, K., El-Naccache, D. W., Sun, Z., and Robertson, E. S. (2015).
EBNA3C regulates p53 through induction of Aurora kinase B. Oncotarget 6,
5788–5803. doi: 10.18632/oncotarget.3310
Jiang, S., Willox, B., Zhou, H., Holthaus, A. M., Wang, A., Zhao, B., et al. (2014).
Epstein-Barr virus nuclear antigen 3C binds to BATF/IRF4 or SPI1/IRF4
composite sites and recruits Sin3A to repress CDKN2A. Proc. Natl. Acad. Sci.
U.S.A. 111, 421–426. doi: 10.1073/pnas.1321704111
Kaiser, C., Laux, G., Eick, D., Jochner, N., Bornkamm, G. W., and Kempkes, B.
(1999). The proto-oncogene c-myc is a direct target gene of Epstein-Barr virus
nuclear antigen 2. J. Virol. 73, 4481–4484.
Kalchschmidt, J. S., Gillman, A. C., Paschos, K., Bazot, Q., Kempkes, B., and Allday,
M. J. (2016). EBNA3C Directs Recruitment of RBPJ (CBF1) to chromatin
during the process of gene repression in EBV Infected B cells. PLoS Pathog.
12:e1005383. doi: 10.1371/journal.ppat.1005383
Kashuba, E., Kashuba, V., Pokrovskaja, K., Klein, G., and Szekely, L. (2000).
Epstein-Barr virus encoded nuclear protein EBNA-3 binds XAP-2, a protein
associated with Hepatitis B virus X antigen. Oncogene 19, 1801–1806. doi:
10.1038/sj.onc.1203501
Kashuba, E., Kashuba, V., Sandalova, T., Klein, G., and Szekely, L. (2002).
Epstein-Barr virus encoded nuclear protein EBNA-3 binds a novel human
uridine kinase/uracil phosphoribosyltransferase. BMC Cell Biol. 3:23. doi:
10.1186/1471-2121-3-23
Kashuba, E., Pokrovskaja, K., Klein, G., and Szekely, L. (1999). Epstein-Barr virus-
encoded nuclear protein EBNA-3 interacts with the epsilon-subunit of the
T-complex protein 1 chaperonin complex. J. Hum. Virol. 2, 33–37.
Kashuba, E., Yurchenko, M., Yenamandra, S. P., Snopok, B., Isaguliants,
M., Klein, G., et al. (2008). EBV-encoded EBNA-6 binds and targets
MRS18-2 to the nucleus, resulting in the disruption of pRb-E2F1
complexes. Proc. Natl. Acad. Sci. U.S.A. 105, 5489–5494. doi: 10.1073/pnas.
0801053105
Kashuba, E. V., Gradin, K., Isaguliants, M., Szekely, L., Poellinger, L., Klein, G.,
et al. (2006). Regulation of transactivation function of the aryl hydrocarbon
receptor by the Epstein-Barr virus-encoded EBNA-3 protein. J. Biol. Chem. 281,
1215–1223. doi: 10.1074/jbc.M509036200
Kaul, R., Murakami, M., Choudhuri, T., and Robertson, E., S. (2007). Epstein-Barr
virus latent nuclear antigens can induce metastasis in a nude mouse model. J.
Virol. 81, 10352–10361. doi: 10.1128/JVI.00886-07
Kaul, R., Murakami, M., Lan, K., Choudhuri, T., and Robertson, E. S. (2009).
EBNA3C can modulate the activities of the transcription factor Necdin
in association with metastasis suppressor protein Nm23-H1. J. Virol. 83,
4871–4883. doi: 10.1128/JVI.02286-08
Kawai, H., Wiederschain, D., and Yuan, Z. M. (2003). Critical contribution of the
MDM2 acidic domain to p53 ubiquitination.Mol. Cell. Biol. 23, 4939–4947. doi:
10.1128/MCB.23.14.4939-4947.2003
Kelly, G. L., Milner, A. E., Baldwin, G. S., Bell, A. I., and Rickinson, A. B. (2006).
Three restricted forms of Epstein-Barr virus latency counteracting apoptosis
in c-myc-expressing Burkitt lymphoma cells. Proc. Natl. Acad. Sci. U.S.A. 103,
14935–14940. doi: 10.1073/pnas.0509988103
Kelly, G. L., Milner, A. E., Tierney, R. J., Croom-Carter, D. S., Altmann, M.,
Rickinson, A. B., et al. (2005). Epstein-Barr virus nuclear antigen 2 (EBNA2)
gene deletion is consistently linked with EBNA3A, -3B, and -3C expression in
Burkitt’s lymphoma cells and with increased resistance to apoptosis. J. Virol. 79,
10709–10717. doi: 10.1128/JVI.79.16.10709-10717.2005
Kempkes, B., Pich, D., Zeidler, R., Sugden, B., and Hammerschmidt, W. (1995).
Immortalization of human B lymphocytes by a plasmid containing 71 kilobase
pairs of Epstein-Barr virus DNA. J. Virol. 69, 231–238.
Knight, J. S., Lan, K., Subramanian, C., and Robertson, E. S. (2003). Epstein-Barr
virus nuclear antigen 3C recruits histone deacetylase activity and associates
with the corepressors mSin3A and NCoR in human B-cell lines. J. Virol. 77,
4261–4272. doi: 10.1128/JVI.77.7.4261-4272.2003
Knight, J. S., and Robertson, E. S. (2004). Epstein-Barr virus nuclear antigen 3C
regulates cyclin A/p27 complexes and enhances cyclin A-dependent kinase
activity. J. Virol. 78, 1981–1991. doi: 10.1128/JVI.78.4.1981-1991.2004
Knight, J. S., Sharma, N., Kalman, D. E., and Robertson, E. S. (2004). A cyclin-
binding motif within the amino-terminal homology domain of EBNA3C binds
cyclin A and modulates cyclin A-dependent kinase activity in Epstein-Barr
virus-infected cells. J. Virol. 78, 12857–12867. doi: 10.1128/JVI.78.23.12857-
12867.2004
Knight, J. S., Sharma, N., and Robertson, E. S. (2005a). Epstein-Barr virus latent
antigen 3C can mediate the degradation of the retinoblastoma protein through
an SCF cellular ubiquitin ligase. Proc. Natl. Acad. Sci. U.S.A. 102, 18562–18566.
doi: 10.1073/pnas.0503886102
Knight, J. S., Sharma, N., and Robertson, E. S. (2005b). SCFSkp2 complex targeted
by Epstein-Barr virus essential nuclear antigen. Mol. Cell. Biol. 25, 1749–1763.
doi: 10.1128/MCB.25.5.1749-1763.2005
Frontiers in Microbiology | www.frontiersin.org 14 April 2016 | Volume 7 | Article 457
Bhattacharjee et al. EBNA-3 Proteins in EBV-Linked Lymphomas
Krauer, K., Buck, M., Flanagan, J., Belzer, D., and Sculley, T. (2004). Identification
of the nuclear localization signals within the Epstein-Barr virus EBNA-6
protein. J. Gen. Virol. 85, 165–172. doi: 10.1099/vir.0.19549-0
Krauer, K. G., Buck, M., Belzer, D. K., Flanagan, J., Chojnowski, G. M., and Sculley,
T. B. (2004a). The Epstein-Barr virus nuclear antigen-6 protein co-localizes
with EBNA-3 and survival of motor neurons protein. Virology 318, 280–294.
doi: 10.1016/j.virol.2003.09.032
Krauer, K. G., Burgess, A., Buck, M., Flanagan, J., Sculley, T. B., and Gabrielli,
B. (2004b). The EBNA-3 gene family proteins disrupt the G2/M checkpoint.
Oncogene 23, 1342–1353. doi: 10.1038/sj.onc.1207253
Krauer, K. G., Kienzle, N., Young, D. B., and Sculley, T. B. (1996). Epstein-Barr
nuclear antigen-3 and -4 interact with RBP-2N, a major isoform of RBP-J kappa
in B lymphocytes. Virology 226, 346–353. doi: 10.1006/viro.1996.0662
Lee, S., Sakakibara, S., Maruo, S., Zhao, B., Calderwood, M. A., Johannsen, E.,
et al. (2009). Epstein-Barr virus nuclear protein 3C domains necessary for
lymphoblastoid cell growth: interaction with RBP-Jkappa regulates TCL1. J.
Virol. 83, 12368–12377. doi: 10.1128/JVI.01403-09
Li, R., and Hayward, S. D. (2011). The Ying-Yang of the virus-host interaction:
control of the DNA damage response. Future Microbiol. 6, 379–383. doi:
10.2217/fmb.11.16
Marshall, D., and Sample, C. (1995). Epstein-Barr virus nuclear antigen 3C is a
transcriptional regulator. J. Virol. 69, 3624–3630.
Marshall, J. C., Collins, J., Marino, N., and Steeg, P. (2010). The Nm23-H1
metastasis suppressor as a translational target. Eur. J. Cancer 46, 1278–1282.
doi: 10.1016/j.ejca.2010.02.042
Maruo, S., Johannsen, E., Illanes, D., Cooper, A., Zhao, B., and Kieff, E.
(2005). Epstein-Barr virus nuclear protein 3A domains essential for growth
of lymphoblasts: transcriptional regulation through RBP-Jkappa/CBF1
is critical. J. Virol. 79, 10171–10179. doi: 10.1128/JVI.79.16.10171-
10179.2005
Maruo, S., Wu, Y., Ishikawa, S., Kanda, T., Iwakiri, D., and Takada, K.
(2006). Epstein-Barr virus nuclear protein EBNA3C is required for cell cycle
progression and growth maintenance of lymphoblastoid cells. Proc. Natl. Acad.
Sci. U.S.A. 103, 19500–19505. doi: 10.1073/pnas.0604919104
Maruo, S., Wu, Y., Ito, T., Kanda, T., Kieff, E. D., and Takada, K. (2009).
Epstein-Barr virus nuclear protein EBNA3C residues critical for maintaining
lymphoblastoid cell growth. Proc. Natl. Acad. Sci. U.S.A. 106, 4419–4424. doi:
10.1073/pnas.0813134106
Maruo, S., Zhao, B., Johannsen, E., Kieff, E., Zou, J., and Takada, K. (2011). Epstein-
Barr virus nuclear antigens 3C and 3A maintain lymphoblastoid cell growth by
repressing p16INK4A and p14ARF expression. Proc. Natl. Acad. Sci. U.S.A. 108,
1919–1924. doi: 10.1073/pnas.1019599108
Matsumoto, K., Taniura, H., Uetsuki, T., and Yoshikawa, K. (2001). Necdin acts as
a transcriptional repressor that interacts with multiple guanosine clusters.Gene
272, 173–179. doi: 10.1016/S0378-1119(01)00544-3
McClellan, M. J., Wood, C. D., Ojeniyi, O., Cooper, T. J., Kanhere, A., West, M. J.,
et al. (2013). Modulation of enhancer looping and differential gene targeting by
Epstein-Barr virus transcription factors directs cellular reprogramming. PLoS
Pathog. 9:e1003636. doi: 10.1371/journal.ppat.1003636
Mirzayans, R., Andrais, B., Scott, A., and Murray, D. (2012). New insights into
p53 signaling and cancer cell response to DNA damage: implications for cancer
therapy. J. Biomed. Biotechnol. 2012:170325. doi: 10.1155/2012/170325
Molyneux, E. M., Rochford, R., Griffin, B., Newton, R., Jackson, G., Menon, G.,
et al. (2012). Burkitt’s lymphoma. Lancet 379, 1234–1244. doi: 10.1016/S0140-
6736(11)61177-X
Murakami, M., Kaul, R., Kumar, P., and Robertson, E. S. (2009). Nucleoside
diphosphate kinase/Nm23 and Epstein-Barr virus. Mol. Cell. Biochem. 329,
131–139. doi: 10.1007/s11010-009-0123-4
Murray, R. J., Kurilla, M. G., Brooks, J. M., Thomas, W. A., Rowe, M.,
Rickinson, A. B., et al. (1992). Identification of target antigens for the human
cytotoxic T cell response to Epstein-Barr virus (EBV): implications for the
immune control of EBV-positive malignancies. J. Exp. Med. 176, 157–168. doi:
10.1084/jem.176.1.157
Musgrove, E. A., Caldon, C. E., Barraclough, J., Stone, A., and Sutherland, R. L.
(2011). Cyclin D as a therapeutic target in cancer.Nat. Rev. Cancer 11, 558–572.
doi: 10.1038/nrc3090
Nikitin, P. A., Yan, C. M., Forte, E., Bocedi, A., Tourigny, J. P., Luftig, M. A., et al.
(2010). An ATM/Chk2-mediated DNA damage-responsive signaling pathway
suppresses Epstein-Barr virus transformation of primary human B cells. Cell
Host Microbe 8, 510–522. doi: 10.1016/j.chom.2010.11.004
Ohashi, M., Holthaus, A. M., Calderwood, M. A., Lai, C. Y., Krastins, B.,
Johannsen, E., et al. (2015). The EBNA3 family of Epstein-Barr virus nuclear
proteins associates with the USP46/USP12 deubiquitination complexes to
regulate lymphoblastoid cell line growth. PLoS Pathog. 11:e1004822. doi:
10.1371/journal.ppat.1004822
Palmero, I., Holder, A., Sinclair, A. J., Dickson, C., and Peters, G. (1993). Cyclins D1
and D2 are differentially expressed in human B-lymphoid cell lines. Oncogene
8, 1049–1054.
Parker, G. A., Crook, T., Bain, M., Sara, E. A., Farrell, P. J., and Allday, M. J. (1996).
Epstein-Barr virus nuclear antigen (EBNA)3C is an immortalizing oncoprotein
with similar properties to adenovirus E1A and papillomavirus E7.Oncogene 13,
2541–2549.
Parker, G. A., Touitou, R., and Allday, M. J. (2000). Epstein-Barr virus EBNA3C
can disrupt multiple cell cycle checkpoints and induce nuclear division
divorced from cytokinesis. Oncogene 19, 700–709. doi: 10.1038/sj.onc.1203327
Paschos, K., Parker, G. A., Watanatanasup, E., White, R. E., and Allday, M. J.
(2012). BIM promoter directly targeted by EBNA3C in polycomb-mediated
repression by EBV. Nucleic Acids Res. 40, 7233–7246. doi: 10.1093/nar/gks391
Paschos, K., Smith, P., Anderton, E.,Middeldorp, J.M.,White, R. E., andAllday,M.
J. (2009). Epstein-barr virus latency in B cells leads to epigenetic repression and
CpGmethylation of the tumour suppressor gene Bim. PLoS Pathog. 5:e1000492.
doi: 10.1371/journal.ppat.1000492
Petti, L., and Kieff, E. (1988). A sixth Epstein-Barr virus nuclear protein (EBNA3B)
is expressed in latently infected growth-transformed lymphocytes. J. Virol. 62,
2173–2178.
Petti, L., Sample, J., Wang, F., and Kieff, E. (1988). A fifth Epstein-Barr virus
nuclear protein (EBNA3C) is expressed in latently infected growth-transformed
lymphocytes. J. Virol. 62, 1330–1338.
Polager, S., and Ginsberg, D. (2009). p53 and E2f: partners in life and death. Nat.
Rev. Cancer 9, 738–748. doi: 10.1038/nrc2718
Radkov, S. A., Touitou, R., Brehm, A., Rowe, M., West, M., Kouzarides, T. J., et al.
(1999). Epstein-Barr virus nuclear antigen 3C interacts with histone deacetylase
to repress transcription. J. Virol. 73, 5688–5697.
Richter-Larrea, J. A., Robles, E. F., Fresquet, V., Beltran, E., Rullan, A. J.,
Agirre, X., et al. (2010). Reversion of epigenetically mediated BIM silencing
overcomes chemoresistance in Burkitt lymphoma. Blood 116, 2531–2542. doi:
10.1182/blood-2010-02-268003
Robertson, E. S., Lin, J., and Kieff, E. (1996). The amino-terminal domains of
Epstein-Barr virus nuclear proteins 3A, 3B, and 3C interact with RBPJ(kappa).
J. Virol. 70, 3068–3074.
Robertson, K. D., Hayward, S. D., Ling, P. D., Samid, D., and Ambinder, R. F.
(1995). Transcriptional activation of the Epstein-Barr virus latency C promoter
after 5-azacytidine treatment: evidence that demethylation at a single CpG site
is crucial.Mol. Cell. Biol. 15, 6150–6159. doi: 10.1128/MCB.15.11.6150
Rosendorff, A., Illanes, D., David, G., Lin, J., Kieff, E., and Johannsen, E. (2004).
EBNA3C coactivation with EBNA2 requires a SUMO homology domain. J.
Virol. 78, 367–377. doi: 10.1128/JVI.78.1.367-377.2004
Russell, M., Berardi, P., Gong, W., and Riabowol, K. (2006). Grow-ING, Age-ING
and Die-ING: ING proteins link cancer, senescence and apoptosis. Exp. Cell
Res. 312, 951–961. doi: 10.1016/j.yexcr.2006.01.020
Saha, A., Bamidele, A., Murakami, M., and Robertson, E. S. (2011a). EBNA3C
attenuates the function of p53 through interaction with inhibitor of growth
family proteins 4 and 5. J. Virol. 85, 2079–2088. doi: 10.1128/JVI.02279-10
Saha, A., Halder, S., Upadhyay, S. K., Lu, J., Kumar, P., Robertson, E. S., et al.
(2011b). Epstein-Barr virus nuclear antigen 3C facilitates G1-S transition by
stabilizing and enhancing the function of cyclin D1. PLoS Pathog. 7:e1001275.
doi: 10.1371/journal.ppat.1001275
Saha, A., Jha, H. C., Upadhyay, S. K., and Robertson, E. S. (2015).
Epigenetic silencing of tumor suppressor genes during in vitro Epstein-
Barr virus infection. Proc. Natl. Acad. Sci. U.S.A. 112, E5199–E5207. doi:
10.1073/pnas.1503806112
Saha, A., Kaul, R., Murakami, M., and Robertson, E. S. (2010). Tumor viruses and
cancer biology: modulating signaling pathways for therapeutic intervention.
Cancer Biol. Ther. 10, 961–978. doi: 10.4161/cbt.10.10.13923
Saha, A., Lu, J., Morizur, L., Upadhyay, S. K., Aj, M. P., and Robertson, E. S. (2012).
E2F1 mediated apoptosis induced by the DNA damage response is blocked by
Frontiers in Microbiology | www.frontiersin.org 15 April 2016 | Volume 7 | Article 457
Bhattacharjee et al. EBNA-3 Proteins in EBV-Linked Lymphomas
EBV nuclear antigen 3C in lymphoblastoid cells. PLoS Pathog. 8:e1002573. doi:
10.1371/journal.ppat.1002573
Saha, A., Murakami, M., Kumar, P., Bajaj, B., Sims, K., and Robertson, E. S.
(2009). Epstein-Barr virus nuclear antigen 3C augments Mdm2-mediated
p53 ubiquitination and degradation by deubiquitinating Mdm2. J. Virol. 83,
4652–4669. doi: 10.1128/JVI.02408-08
Saha, A., and Robertson, E. S. (2011a). Epstein-Barr virus-associated B-cell
lymphomas: pathogenesis and clinical outcomes. Clin. Cancer Res. 17,
3056–3063. doi: 10.1158/1078-0432.CCR-10-2578
Saha, A., and Robertson, E. S. (2011b). Functional modulation of the metastatic
suppressor Nm23-H1 by oncogenic viruses. FEBS Lett. 585, 3174–3184. doi:
10.1016/j.febslet.2011.08.007
Saha, A., and Robertson, E. S. (2013). Impact of EBV essential nuclear protein
EBNA-3C on B-cell proliferation and apoptosis. Future Microbiol. 8, 323–352.
doi: 10.2217/fmb.12.147
Sahu, S. K., Mohanty, S., Kumar, A., Kundu, C. N., Verma, S. C., and Choudhuri,
T. (2014). Epstein-Barr virus nuclear antigen 3C interact with p73: interplay
between a viral oncoprotein and cellular tumor suppressor. Virology 448,
333–343. doi: 10.1016/j.virol.2013.10.023
Sandoval, J., and Esteller, M. (2012). Cancer epigenomics: beyond genomics. Curr.
Opin. Genet. Dev. 22, 50–55. doi: 10.1016/j.gde.2012.02.008
Skalska, L., White, R. E., Franz, M., Ruhmann, M., and Allday, M. J. (2010).
Epigenetic repression of p16(INK4A) by latent Epstein-Barr virus requires the
interaction of EBNA3A and EBNA3C with CtBP. PLoS Pathog. 6:e1000951. doi:
10.1371/journal.ppat.1000951
Skalska, L., White, R. E., Parker, G. A., Turro, E., Sinclair, A. J., and Allday, M. J.,
et al. (2013). Induction of p16(INK4a) is themajor barrier to proliferation when
Epstein-Barr virus (EBV) transforms primary B cells into lymphoblastoid cell
lines. PLoS Pathog. 9:e1003187. doi: 10.1371/journal.ppat.1003187
Subramanian, C., Cotter, M. II, and Robertson, E. S. (2001). Epstein-Barr virus
nuclear protein EBNA-3C interacts with the human metastatic suppressor
Nm23-H1: a molecular link to cancer metastasis. Nat. Med. 7, 350–355. doi:
10.1038/85499
Subramanian, C., Hasan, S., Rowe, M., Hottiger, M., Orre, R., and Robertson, E. S.
(2002a). Epstein-Barr virus nuclear antigen 3C and prothymosin alpha interact
with the p300 transcriptional coactivator at the CH1 and CH3/HAT domains
and cooperate in regulation of transcription and histone acetylation. J. Virol.
76, 4699–4708. doi: 10.1128/JVI.76.10.4699-4708.2002
Subramanian, C., Knight, J. S., and Robertson, E. S. (2002b). The Epstein Barr
nuclear antigen EBNA3C regulates transcription, cell transformation and cell
migration. Front. Biosci. 7, d704–d716. doi: 10.2741/subraman
Subramanian, C., and Robertson, E. S. (2002). The metastatic suppressor Nm23-
H1 interacts with EBNA3C at sequences located between the glutamine- and
proline-rich domains and can cooperate in activation of transcription. J. Virol.
76, 8702–8709. doi: 10.1128/JVI.76.17.8702-8709.2002
Tomkinson, B., and Kieff, E. (1992). Use of second-site homologous recombination
to demonstrate that Epstein-Barr virus nuclear protein 3B is not important
for lymphocyte infection or growth transformation in vitro. J. Virol. 66,
2893–2903.
Tomkinson, B., Robertson, E., and Kieff, E. (1993). Epstein-Barr virus nuclear
proteins EBNA-3A and EBNA-3C are essential for B-lymphocyte growth
transformation. J. Virol. 67, 2014–2025.
Touitou, R., Hickabottom, M., Parker, G., Crook, T., and Allday, M. J. (2001).
Physical and functional interactions between the corepressor CtBP and the
Epstein-Barr virus nuclear antigen EBNA3C. J. Virol. 75, 7749–7755. doi:
10.1128/JVI.75.16.7749-7755.2001
Touitou, R., O’Nions, J., Heaney, J., and Allday, M. J. (2005). Epstein-Barr virus
EBNA3 proteins bind to the C8/alpha7 subunit of the 20S proteasome and are
degraded by 20S proteasomes in vitro, but are very stable in latently infected B
cells. J. Gen. Virol. 86, 1269–1277. doi: 10.1099/vir.0.80763-0
von der Lehr, N., Johansson, S., Wu, S., Bahram, F., Castell, A., and Cetinkaya, C.
(2003). The F-box protein Skp2 participates in c-Myc proteosomal degradation
and acts as a cofactor for c-Myc-regulated transcription. Mol. Cell 11,
1189–1200. doi: 10.1016/S1097-2765(03)00193-X
Wade, M., and Allday, M. J. (2000). Epstein-Barr virus suppresses a G(2)/M
checkpoint activated by genotoxins. Mol. Cell. Biol. 20, 1344–1360. doi:
10.1128/MCB.20.4.1344-1360.2000
Waltzer, L., Perricaudet, M., Sergeant, A., and Manet, E. (1996). Epstein-Barr virus
EBNA3A and EBNA3C proteins both repress RBP-J kappa-EBNA2-activated
transcription by inhibiting the binding of RBP-J kappa to DNA. J. Virol. 70,
5909–5915.
Wang, F., Kikutani, H., Tsang, S. F., Kishimoto, T., and Kieff, E. (1991). Epstein-
Barr virus nuclear protein 2 transactivates a cis-acting CD23 DNA element. J.
Virol. 65, 4101–4106.
West, M. J. (2006). Structure and function of the Epstein-Barr virus
transcription factor, EBNA 3C. Curr. Protein Pept. Sci. 7, 123–136. doi:
10.2174/138920306776359777
White, R. E., Groves, I. J., Turro, E., Yee, J., Kremmer, E., and Allday, M.
J. (2010). Extensive co-operation between the Epstein-Barr virus EBNA3
proteins in the manipulation of host gene expression and epigenetic
chromatin modification. PLoS ONE 5:e13979. doi: 10.1371/journal.pone.
0013979
Wu, Z., and Yu, Q. (2009). E2F1-mediated apoptosis as a target of cancer therapy.
Curr. Mol. Pharmacol. 2, 149–160. doi: 10.2174/1874467210902020149
Yan, X., Mouillet, J. F., Ou, Q., and Sadovsky, Y. (2003). A novel domain within
the DEAD-box protein DP103 is essential for transcriptional repression and
helicase activity. Mol. Cell. Biol. 23, 414–423. doi: 10.1128/MCB.23.1.414-
423.2003
Yi, F., Saha, A., Murakami, M., Kumar, P., Knight, J. S., Robertson, E.
S., et al. (2009). Epstein-Barr virus nuclear antigen 3C targets p53 and
modulates its transcriptional and apoptotic activities. Virology 388, 236–247.
doi: 10.1016/j.virol.2009.03.027
Young, L. S., and Rickinson, A. B. (2004). Epstein-Barr virus: 40 years on.Nat. Rev.
Cancer 4, 757–768. doi: 10.1038/nrc1452
Young, P., Anderton, E., Paschos, K., White, R., and Allday, M. J. (2008). Epstein-
Barr virus nuclear antigen (EBNA) 3A induces the expression of and interacts
with a subset of chaperones and co-chaperones. J. Gen. Virol. 89, 866–877. doi:
10.1099/vir.0.83414-0
Zhao, B., Mar, J. C., Maruo, S., Lee, S., Gewurz, B. E., Johannsen, E., et al. (2010).
Epstein-Barr virus nuclear antigen 3C regulated genes in lymphoblastoid
cell lines. Proc. Natl. Acad. Sci. U.SA.. 108, 337–342. doi: 10.1073/pnas.1017
419108
Zhao, B., Marshall, D. R., and Sample, C. E. (1996). A conserved domain of the
Epstein-Barr virus nuclear antigens 3A and 3C binds to a discrete domain of
Jkappa. J. Virol. 70, 4228–4236.
Zhao, B., and Sample, C. E. (2000). Epstein-barr virus nuclear antigen 3C activates
the latent membrane protein 1 promoter in the presence of Epstein-Barr virus
nuclear antigen 2 through sequences encompassing an spi-1/Spi-B binding site.
J. Virol. 74, 5151–5160. doi: 10.1128/JVI.74.11.5151-5160.2000
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2016 Bhattacharjee, Ghosh Roy, Bose and Saha. This is an open-access
article distributed under the terms of the Creative Commons Attribution License (CC
BY). The use, distribution or reproduction in other forums is permitted, provided the
original author(s) or licensor are credited and that the original publication in this
journal is cited, in accordance with accepted academic practice. No use, distribution
or reproduction is permitted which does not comply with these terms.
Frontiers in Microbiology | www.frontiersin.org 16 April 2016 | Volume 7 | Article 457
